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Abstract 
Hepatoma cells (HepG2 cells) were incubated for 24 h with different saturated fatty acids at 
different concentrations to examine a possible regulation of mRNA expression of 
adiponectin receptor 1 and 2. The results showed that incubation with saturated FAs had a 
tendency to reduce the expression of adiponectin receptor 1 in HepG2 cells, whereas no 
change was observed for adiponectin receptor 2. The fatty acid analogues TTA, TTTA and 
αTTA did not reduce the amount of either adiponectin receptor 1 or 2.   
Adiponectin receptor 3, T-cadherin, was cloned, and the expression of T-cadherin in a 
selection of tissues was studied. The expression of T-cadherin was highest in fetal brain, 
heart, uterus, lung whole and skeletal muscle, whereas the amount in liver was barely 
detectable.  
Experiments with human myotubes were performed to examine if incubation with full-
length, globular and trimer adiponectin altered oxidation of fatty acid (oleic acid) or if trimer 
adiponectin altered glucose oxidation. Myotubes from three different donor groups, lean, 
obese and T2D, were used in these experiments. Trimer adiponectin showed a tendency to 
increase glucose oxidation. Globular adiponectin showed a tendency to increase oleic acid 
oxidation more than full-length adiponectin and trimer adiponectin.  
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Abbreviations 
AMPK AMP-activated protein kinase 
AR1  adiponectin receptor 1  
AR2  adiponectin receptor 2 
ASM  acid soluble metabolites 
αTTA  alpha methyl tetradecyl thioacetic acid 
BSA  bovine serum albumin 
CAR  cell associated radiolabel 
DMEM Dulbecco’s modified Eagle’s medium 
FFA  free fatty acids 
flAdn  full length adiponectin 
gAdn  globular adiponectin 
HepA  heptadecanoic acid  
LaA  lauric acid (12:0) 
LB  Lauria-Bertani 
LDH  lactate dehydrogenase 
MA  myristic acid (14:0) 
MEM  minimal essential medium 
mRNA messenger ribonucleic acid 
OA  oleic acid (18:1, n-9) 
PA  palmitic acid (16:0) 
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PBS Phosphate Buffered Saline (Dulbecco’s with Calcium Chloride and 
Magnesium Chloride)  
RPL27  ribosomal protein 27 
RT-PCR Reverse transcriptase- polymerase chain reaction  
StA  stearic acid (18:0) 
tAdn  trimer adiponectin 
T-cad  T-cadherin receptor/adiponectin receptor 3 
TG  triglycerides  
TTA  tetradecyl thioacetic acid (CH3-(CH2)13-S-CH2-COOH) 
TTTA  triple tetradecyl thioacetic acid 
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1. Introduction 
1.1 Adiponectin 
Adiponectin is a hormone that is secreted by differentiated adipocytes and bone-forming 
cells (1). Plasma concentrations in humans range from 3 to 30 µg/mL and are inversely 
proportional to body fat content. Adiponectin is the most abundantly secreted adipokine, 
making up to 0.01% of circulating protein in serum (2). The protein consists of 244 amino 
acids (30 kDa), is related to the complement 1q family and contains a carboxyl-terminal 
globular domain and a collagenous domain at the amino terminal (2). Circulating 
adiponectin levels are decreased in obese and insulin resistant subjects and the levels seems 
to decrease in parallel with progression of insulin resistance and type 2 diabetes. Elevated 
plasma adiponectin is strongly and independently associated with reduced risk of developing 
type 2 diabetes in healthy individuals (3). Adiponectin is encoded by the APM1 gene which 
maps to chromosome 3q27, a region identified as a susceptibility locus for metabolic 
syndrome and type 2-diabetes (3). 
Adiponectin was originally identified by four independent groups using different 
experimental approaches and has therefore also been called Acrp30, GBP28, apM1 and 
AdipoQ in the past (4-6). Two different adiponectin receptors have been identified, the 
adiponectin receptor 1 (AR1) that is ubiquitously expressed in the body, and the adiponectin 
receptor 2 (AR2), whose expression is more restricted to skeletal muscle and liver. A third 
adiponectin receptor, T-cadherin, was later identified.  The AR1 exhibits high affinity for 
globular adiponectin and low affinity for full-length adiponectin (7). The AR2 shows 
intermediate affinity for both types of adiponectin. The identification of AR1 and AR2 has 
helped us to gain a better understanding of the effects of adiponectin in different tissues. 
Adiponectin displays a wide range of effects, including insulin sensitivity, activation of 
peroxisome proliferator activator receptor α (PPARα) ligand pathways and AMP protein 
kinase (AMPK), and anti-atherosclerotic effects. Down-stream of the adiponectin receptors 
activation of AMPK followed by inhibition of acetyl coenzyme A carboxylase (ACC) and 
stimulation of PPARα is essential for the effect of adiponectin (fig 1.2). Activation of 
AMPK results in stimulation of proteins involved in fatty acid (FA) transport and oxidation, 
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and an increased glucose uptake in muscle. PPARα activation causes increased FA oxidation 
in muscle and liver and increases the fasting response in liver. The adiponectin gene contains 
response elements for peroxisome proliferator activator receptor γ (PPARγ), a key regulator 
of glucose and lipid metabolism. Total energy expenditure, especially in hyperinsulinaemic 
conditions, increase with elevated serum adiponectin levels (2).  
Adiponectin increases AMP-activated protein kinase activation and FA oxidation, and plays 
a central role in the regulation of food consumption. In the lean state adiponectin induces FA 
uptake into storage depots. When adipocytes reach a certain size, secretion is switched off to 
prevent further lipid accumulation (2).  
Regulation of physiological responses to elevated serum adiponectin is complicated and 
occurs at several levels, including formation of oligomers, enzymatic cleavage and 
availability of its receptor isoforms. Adiponectin circulates in plasma as three distinct 
oligomers, trimers, hexamers (low molecular weight species) and high molecular weight 
(HMW) species. It may exist as full-length or smaller, globular fragments. However, almost 
all adiponectin exists as full-length adiponectin in plasma (8). An important function of 
HMW adiponectin in insulin sensitivity was suggested in 2001 by three independent groups 
(8). The hypothesis was that HMW adiponectin may be converted into a biologically active 
form in response to metabolic challenge, through reduction and proteolytic cleavage (3). 
Adiponectin promotes oxidation of FA in muscle and synthesis of different adiponectin 
receptors in liver and other tissues, thus decreasing tissue triglyceride (TG) content and 
upregulation of insulin signaling. Increased tissue TG content can interfere with insulin-
stimulated phosphatidylinositol (PI) 3 kinase activation and subsequent glucose transporter 4 
(GLUT4) translocation and glucose uptake. This may lead to insulin resistance in muscle, 
and a decrease in TG by the action of adiponectin through its receptors that may contribute 
to improved insulin signal transduction (8).  
T-cadherin (T-cad) is the third adiponectin receptor, and has also been called H (heart)-
cadherin and cadherin-13 (CDH13). It is an atypical glycosylphosphatidylinositol-(GPI) 
anchored extracellular protein, member of the cadherin superfamily (9). T-cad is a receptor 
for hexameric and HMW forms of adiponectin, but not for the trimeric and globular 
adiponectin. Low-density lipoproteins (LDL) interfere with the normal function of T-cad 
because of binding to the receptor in endothelial cells (10). Only eukaryotically expressed 
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adiponectin bind to T-cad, implying that posttranslational modifications of adiponectin are 
critical for binding (3). T-cad is widely expressed in brain and the cardiovascular system, 
and lower levels are found in muscle. T-cad is expressed in low amounts in liver (10) and its 
tissue distribution is differing from that of AR1 and AR2. T-cad is regulated in a complex 
manner indicating a role in hormone and drug-induced changes in bone tissue. Adiponectin 
levels have been shown to be inversely associated with bone mineral density (10). T-cad has 
been shown to be involved in fracture healing (10). The function of T-cad is not well 
understood, but it may act as a co-receptor for an as yet unidentified signaling receptor 
through which adiponectin transmits metabolic signals (11). 
T-cad regulates growth of cells in the nervous system. It was reduced in a glioblastoma cell 
line and reexpression of T-cad induced growth arrest (11). T-cad appears to be a negative 
regulator of cell growth, because it regulates motor axon projection in the embryonic 
nervous system via contact inhibition (10). T-cad is also found to protect endothelial cells 
from oxidative stress-induced apoptosis through activation of PI3K/Akt/mTOR survival 
signal pathway and suppression of the p38 MAPK proapoptotic pathway (9).  
There is a potential for adiponectin replacement therapy in insulin resistance and related 
disorders if looking at the beneficial effect of adiponectin observed in animal studies. There 
is a co-variation in the amount of fat tissue and the amount of circulating adiponectin, where 
increasing amount of fat tissue reduces the amount of adiponectin and thus worsen the 
insulin resistance (3). Knock-out of the adiponectin gene in mice is associated with insulin 
resistance and low mitochondrial content and reduced mitochondrial enzyme activity in 
skeletal muscle (12). Acute adiponectin incubation  in mice decreases insulin resistance, 
plasma FFAs and the triglyceride content of muscle and liver, and increases expression of 
genes involved in FA oxidation and energy expenditure (13). Glucocorticoids have been 
shown to decrease serum adiponectin levels in normal subjects treated with hydrocortisone 
and in patients with Cushing’s syndrome (10). It has been proposed that increasing the 
expression of AR1 and AR2 may improve insulin sensitivity and reduce the risk of 
developing T2D (14). 
Adiponectin’s anti-atherogenicity might lead to the development of new therapeutic 
strategies for cardiovascular disease, diabetes mellitus and even the metabolic syndrome. 
Given the high plasma levels of adiponectin in humans, direct administration of adiponectin 
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protein to individuals with chronic disease as a type of therapy might be difficult. The reason 
for this can be that the underlying mechanisms that cause problems in maintaining high 
plasma levels of adiponectin are still present. The search for enhancers of endogenous 
adiponectin synthesis or a method for reducing the clearance of adiponectin might be the 
most practical way for therapeutic application related to adiponectin. Thiazolidinedione 
derivatives have been shown to potently increase adiponectin synthesis (15).  
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Myotubes 
Myotubes grown from satellite cells have been used as an in vitro muscle cell model. 
Experiments have been performed with human myotubes grown from muscle biopsies from 
three different donors. The myotubes have been preincubated with adiponectin and later 
incubated for 4 h with [1-14C]oleic acid containing medium (fig 1.1).  
 
Day 0
   
Day 2
 
Day 4
   
Day 6
 
Figure 1.1 Photographs (x20) of differentiation of satellite cells to myotubes. 
Morphological appearance (phase contrast microscopy) during differentiation of a 
human satellite cell culture at day 0, 2, 4 and 6 after start of differentiation in insulin 
containing differentiation medium (pictures by Vigdis Aas). 
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Adiponectin and the mechanism of insulin sensitizing effect  
Figure 1.2 Adiponectin related to an insulin sensitizing effect. The proposed 
mechanism by which adiponectin stimulate FA oxidation and reduce lipid 
accumulation (16). There is a strong correlation between abnormal fatty acid (FA) 
metabolism and the development of insulin resistance in skeletal muscle. Globular 
adiponectin interacts with AR1 in skeletal muscle. Adiponectin stimulates 
phosphorylation of AMPK and ACC, and stimulates/increase FA oxidation and 
decrease TG storage in muscle. FA inhibits the translocation of GLUT-4 to the cell 
membrane and this result in a reduction in glucose uptake (16). 
1.2 Adipose tissue and free fatty acids   
Circulating free fatty acids (FFAs) derived from adipocytes are elevated in many insulin 
resistance states. Increased lipolysis in adipocytes due to poor effect of insulin, results in 
increased FA release from adipocytes. An elevation in circulating FA in obese patients 
results in increased uptake of FA and excess deposition of lipids within the muscle cell if the 
FA cannot be oxidized (16). The FAs are stored in muscle cells instead of adipose tissue and 
interfere with the normal function. Visceral fat is less sensitive to insulin than subcutaneous 
fat. This causes direct flux of adipocyte derived FAs through the portal vein into the liver, 
and can stimulate glucose production, thus providing a signal for both insulin action and 
insulin resistance in the liver (13). Although insulin does not stimulate hepatic glucose 
uptake, it blocks/inhibits glycogenolysis and gluconeogenesis, and stimulates glycogen 
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synthesis, thus regulating fasting glucose levels (13). Elevated FFAs might cause 
accumulation of fat in muscle, liver and/or β-cells, which may interfere with different 
metabolic pathways and signalling (17). Insulin resistance is associated with impaired 
skeletal muscle oxidation capacity and reduced mitochondrial number and function. Lipid 
oversupply results in change in Randle glucose fatty acid cycle (fig 1.3), alter membrane 
lipid composition, promote triglyceride accumulation, increase ceramide biosynthesis, 
increase hexosamine biosynthesis and interact with insulin signalling and glucose disposal 
(18). Skeletal muscle has been considered one of the primary targets for understanding 
mechanisms for development of T2D and insulin resistance, mainly because it is the most 
important glucose absorptive organ. 
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Randle glucose-fatty acid cycle and insulin resistance 
 
Figure 1.3 Schema of potential sites of free fatty acid action on insulin mediated 
glucose metabolism in skeletal muscle and those sites (*) hypothesized to be affected 
by Randle et al (18). G-6-P; glucose-6-phospate; G-1-P, glucose-1-phospate; F-6-P, 
fructose-6-phospate, F-1,6,-P; fructose 1,6 biphospate. Free fatty acids induce insulin 
resistance in humans by initial inhibition of glucose transport/phosphorylation. This is then 
followed by an approximately 50% reduction in both the rate of muscle glycogen synthesis 
and glucose oxidation. A reduction in carbohydrate oxidation is responsible for one-third, 
while impairment of non-oxidative glucose metabolism (mostly glycogen synthesis) 
accounted for two-thirds of the fatty acid-dependent decrease in glucose uptake (18).  
 
 17
1.3 Aims  
The purpose of this project was to study the effects of incubating hepatoma (HepG2) cells 
with different fatty acids (FAs), and measure expression of adiponectin receptor (1 and 2) 
mRNA.  
To clone the third adiponectin receptor, T-cadherin, and study its expression in a tissue panel 
and in several cell lines.  
To study the effects of incubating HepG2 cells with different FAs and measure expression of 
of T-cadherin receptor mRNA. 
To study chronic and acute effects of full-length, globular and trimer adiponectin on oleic 
acid oxidation and trimer adiponectin on glucose oxidation, in human myotubes.  
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2. Materials and Methods 
2.1 Materials  
Dulbecco’s modified eagle medium (DMEM), fetal calf serum (FCS), penicillin-
streptomycin 10000 U/mL-10000 mg/mL was obtained from Gibco, Paisley, UK. Ultroser G 
was obtained from BioSepra, Process Division of Ciphergen Biosystems Inc, Paris, France. 
[1-14C]sodium bicarbonate, [6-14C]glucose and [1-14C]oleic acid were obtained from 
American Radiolabel Chemical Inc, MO, USA. Insulin Actrapid was obtained from Novo 
Nordisk, Bagsværd, Denmark. Bio-Rad protein assay dye reagent concentrate was obtained 
from Bio-Rad Laboratories, Oslo, Norway. LDH assay Cytotoxicity Detection Kit and 
TaqMan Reverse Transcription Reagents were obtained from Roche Diagnostics, 
Mannheim, Germany. 12-well cell culture cluster plates were obtained from Corning 
Incorporated-Costar, NY, USA.  96-well plates were obtained from Greiner Bio-One, 
Frickenhausen, Germany. PCR, PfuUltraTMHigh-Fidelity DNA Polymerase was obtained 
from Stratagene, TX, USA. Reverse Transcriptase; Gene Amp®PCR System 9700 was 
obtained from Applied Biosystems international, USA.  Agarose gel was obtained from 
SeaKem LE Agarose-Cambrex Bio Science, Rockland, USA. QIAquick gel Extraction kit 
was obtained from Qiagen, Hilden, Germany. pEntr Directional TOPO cloning kit and 
TRIzol Reagent were obtained from Invitrogen, Carlsbad, USA. Jetquick Plasmid Miniprep 
and Maxiprep were obtained from Genomed, Löhne, Germany.  All reagents for cell culture, 
L-carnitine and bovine serum albumin-essentially FA free were obtained from Sigma Chem. 
Co, St.Louis, MO, USA. All other chemicals used were standard commercial high purity 
materials. 
2.2 HepG2 cells 
Human hepatoma cells, HepG2, were obtained from the American Tissue Culture Collection 
(ATCC, No HB-8065, Manassas USA). The experiments that were performed with these 
cells were a continuation of previous experiments (19;20). 
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The cells were cultured in minimal essential medium (MEM, M2279) containing 1 g/L 
glucose, supplemented with 10 % heat-inactivated fetal calf serum (FCS, F7524), 10.000 
U/mL penicillin, 10 mg/mL streptomycin (P/S, P4333), 200 mM L-glutamine (G7513), 
100X non-essential amino acids (M7145) and 11 mg/mL sodium pyruvate (S8636). 
The cells were grown in biocoat flasks in an incubator maintaining controlled, constant 
temperature (37ºC) and CO2 enriched atmosphere (5 %). The wells/flasks contained 
approximately 1 ml medium per 10 cm2. The medium was changed every 2-3 days until the 
cells reached confluence.  
Trypsination was performed using 0.25 % sterile filtered trypsin EDTA solution. Old 
medium was removed and the wells were washed twice with 1 ml trypsin before they were 
added 3 ml trypsin and put in the incubator holding 37ºC for 5 -15 min until they detached.  
The cell suspension was transferred to a 50 ml falcon tube and 6 ml of the cell medium were 
added to inactivate the trypsins action. The suspension was centrifuged at 13000rpm for 3 
min at room temperature. The supernatant was discharged and the cell pellet re suspended in 
DMEM medium and the cell concentration determined by using a counting chamber, 
hemocytometer. The suspension was then diluted and the cells sub cultured into new biocoat 
flasks, or 12 well plates for experiments. 
2.2.1 Experiments with HepG cells 
The cells were seeded into 12 well cells plates approximately 7 days before experiments 
were performed. For adiponectin receptor regulation studies, the cells were given different 
fatty acids (FAs) for various time periods, usually 24 h.  
The FAs were diluted with DMEM medium to concentrations of 200, 100 and 50 µM, before 
they were added to the HepG2 cells. Two parallels of each concentration of the different FAs 
were added to the wells and the cells were incubated 24 h before they were harvested. The 
cell medium was removed and a LDH (lactate dehydrogenase) assay was performed to 
assess plasma membrane damage level. The method was performed according to instruction 
manual. 50 µl of the cell medium was transferred to a 96-well plate with two parallels of 
each tube. Reaction mixture was prepared shortly before use, as described in manual, and 
was added to the cells. The plates were covered by aluminum foil. Bobbles in the wells were 
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removed, and the plates were stored in an incubator at 37˚C for 30 min. For a measure of the 
level of 100 % cell lysis, diluted Triton was added. 50 µl LDH reagent was added to each 
well.  
The result was detected by a spectrophotometric microplate reader (Titertek Multiscan Plus 
(MK-ІІ), LabSystems, Helsinki) at 492nm. 
2.2.2 RNA isolation with TRIzol 
The RNA from the cells was isolated using TRIzol Reagent (Invitrogen Life Technologies, 
Carlsbad, CA), maintaining the integrity of RNA, while disrupting cells and dissolving cell 
components. All tubes containing RNA were kept cool on ice to avoid room temperature 
RNase degradation. Each well was added 0.5 ml TRIzol Reagent, scraped with a cell scrape 
and lysate from two wells was transferred to 1.5 ml Eppendorf tubes. At this stage the lysate 
was stored at -70˚C if not processed right away. 
The tubes were kept at 30˚C for 5 min and then added 0.2 ml chloroform. This was shaken 
hard in horizontal position for at least 15 seconds and then kept 2-3 min at room 
temperature. Then the tubes were spun 15 min 13000 rpm 4˚C and put in a rack. The 
separated clear upper phase consisting of water and RNA was transferred to 1.5 ml 
Eppendorf tubes on ice. If the upper phase was contaminated by mistake, the tubes were re-
centrifuged. RNA was precipitated by adding 0.5 ml isopropanol to the 1.5 ml Eppendorf 
tubes. The tubes were vortexed, let standing 10 min RT, spun 10 min 13000 rpm 4˚C and 
then the supernatant was discarded. Pellet was washed by adding 1 ml 75 % ethanol in 
DEPC-water then vortex, spun 5 min 8000 rpm 4˚C and all supernatant discarded, leaving 
pellet almost dry. Then the pellet was air dried 5-10 min (before pellet was getting invisible) 
then resolved in 20 µl DEPC-water, pipetted up and down, let standing for 10 min in 60˚C, 
vortexed, spun down and 1 µl was removed for Optical density (OD, 1/100X) measurement. 
The RNA was stored at -70˚C. 
2.2.3 Measure RNA concentration  
RNA quality and quantity were determined spectrophotometrically based on optical density 
(OD) measurements on the Heλiosγ (Thermo Spectronic, Cambridge, UK). 1 µl of each 
sample was diluted in 99 µl DEPC-water. OD 260nm (OD 260nm=1=40 ng/µl) was 
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measured and concentration calculated. The RNA was diluted to a concentration 0.3 µg/µl 
and the samples were prepared for reverse transcriptase.  
Alternatively, the Nanodrop method was used, eliminating the need of pre-diluting sample. 
2.2.4  Reverse Transcription, RT-PCR 
TaqMan Reverse Transcription Reagents (Roche diagnostics, Mannheim, Germany) were 
used to convert a maximum of 2 µg total RNA to cDNA. Random hexamers were used 
(appendix). 
All non-enzymatic components were combined and vortexed briefly. Enzymatic components 
were added. 28 µl of the mixture was transferred to glass capillaries, and 2 µl of the different 
samples of RNA (0.3 µg/µl) was then added. The tubes were capped and centrifuged to 
collect liquid at the bottom.  
The instrument used was Touchgene Gradient machine (Cambridge, UK).   
Thermal cycling parameters were incubation 25˚C for 10 min, reverse transcription 48˚C for 
30 min and reverse transcriptase inactivation 95˚C for 5 min. A final hold at 4˚C for samples 
was obtained. Obtained cDNA was stored at -20˚C.  
2.2.5 Real Time Polymerase Chain Reaction, RT-PCR 
Target gene LightCycler Kit (FastStart DNA Master SYBR Green Ι) and master mix 
supplied in kits from Roche Diagnostics (Mannheim, Germany) was used for amplification 
and detection of RNA. Primers were provided from Eurogentech (Seraing, Belgium).  
Adiponectin receptors 1 and 2:  
(5`-CTTCTACTGCTCCCCACAGC-3` and 5`-GATAGCGACTCCCGAAACAG-3`) and 
(5`-CAACTGGATGGTACACGA-3`and 5`-AGAACGTACCTGTGGC-3`). 
Housekeeping gene RPL27:  
(5`-CCTACAGCCATGCTCT-3` and 5`-CATCCTTATTGACGACATG-3`). 
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Duplicate PCR reactions were performed in narrow glass capillaries with a reaction volume 
of 20 µl that include 2 µl cDNA. DEPC water was added instead of cDNA to one of the 
capillaries as a negative control. RPL27 was used to prove the integrity of the RNA and was 
tested in parallel to AR 1 and 2. 
The PCR program started with a denaturizing step at 95˚C for 10 min, then temperature 
cycling was initiated and consisted of denaturizing at 95˚C for 10 sec, hybridization at 55˚C 
for AR1 and RPL27 and 60˚C for AR2 for 3 sec and elongation at 72˚C for 10 sec. A final 
hold for 30 sec at 40˚C was obtained. Approximately 45 cycles were performed. 
2.3 Cloning of human adiponectin receptor 3  
For the cloning of human adiponectin receptor 3 (T-cadherin, CDH13), a blunt-end PCR 
product was cloned directionally into the pENTRTM D-TOPO entry vector.  
The primers hTCad-CDS-L (5’-CAC-CAT-GCA-GCC-GAG-AAC-TCC-GCT-CGT-3’) and 
hTCad-CDS-R (5’-TCA-CAG-ACA-AGC-TAA-GCT-GAA-GA-3’) from Eurogentec 
(Seraing, Belgium) were designed based on the mRNA sequence of CDH13 (GeneBank, 
NCBI sequence viewer) to amplify the translated region (121bp-2262bp)  with use of 
PfuUltraTM High-Fidelity DNA Polymerase-kit (Stratagene, TX-USA), according to 
manufacturer’s instructions with some modifications:  
The total reaction volume for the amplification reaction was 50 µl: 36.6 µl MQ-water 
(Millipore, Bedford, USA), 5 µl 10X buffer that comes with enzymes, 4 µl dNTPs 
(4x2.5mM/10mM total), 1 µl cDNA as template (nuclease free water was used as a negative 
control), 1 µl primer hTCad-CDS-R (25 µM) 1 µl primer hTCad-CDS-L (25 µM) and 1 µl 
PfuUltra High-Fidelity DNA polymerase (2.5 U/µl). Total RNA from heart (Human total 
RNA master panel II, BD bioscience) was first Reverse Transcripted to cDNA and then used 
as template. The use of heart cDNA gave a single band monitored by agarose gel 
electrophoresis 1% (110 V 90 min. Size of the band 2141 bp). Monocyte total RNA U937 
(ATCC CRL-1593.2™, Manassas USA) was first Reverse Transcripted to cDNA and then 
used as template, but had to be replaced with heart cDNA (data not shown). 
The instrument used was Gene Amp PCR System 9700 (Applied Biosystems, USA).   
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Thermal cycling parameters were initially denaturizing 95˚C for 2 min, 95˚C for 30 sec, 
55˚C for 30 sec, 72˚C for 2 min and 30 sec, for approximately 30 cycles and a final 
elongation 72˚C for 10 min was obtained. 
After the PCR reaction was completed 10 µl of the product was analyzed by agarose gel 
electrophoresis 1 %, with 1 kb Plus ladder (Invitrogen Life Technologies, Carlsbad, CA) as a 
measure of fragment size. The gel was run at 100 V for approximately 90 min. The desired 
product was 2141 base pairs (bp) and the size was confirmed by comparing the band with 
ladder bands of specific sizes. 
The gel product DNA was purified by using QIAquick Gel Extraction Kit Protocol. This 
procedure was performed according to the manufacturer’s instructions.   
2.3.1 QIAquick Gel extraction 
The DNA fragment was cut out of the agarose gel using a UV light plate. This piece was put 
into an Eppendorf tube and the weight was measured. QG buffer was added and the tube was 
incubated at 50˚C in a water bath for 10 min, or until the gel piece was solved. The yellow 
solution was then transferred to a column in which maximal volume was 0.8 ml, with an 
Eppendorf tube underneath. The column was then centrifuged at 13000 rpm for 1 min. 
The volume collected in the tube was discharged and 0.5 ml QG buffer was added to the 
column and centrifuged one more time at 13000 rpm for 1 min.  
0.75 ml PE buffer was added to wash the column, let stand 2-5 min and then centrifuged for 
1 min. The liquid in the tube was discharged and the column centrifuged one more time for 1 
min.  
The column was transferred to a new tube and 50 µl EB buffer (10mM Tris-Cl, pH 8.5) was 
added in the center of the column and centrifuged 1 min. 
The elute was stored at -20 ˚C.        
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2.3.2 Measurement of  DNA concentration  
The concentration of DNA was measured with use of agarose gel electrophoresis 1%  100 V 
for 3 h and 1 kb Plus ladder as a measure of the size of the bands. The 2141-bp band 
contained approximately 8% of the mass applied to the gel. Dilution lines of the 1 kb Plus 
ladder was used and the concentration of DNA determined visually by comparing the size of 
the bands with the size of the different dilutions. The concentration of DNA was then 
calculated. 
2.3.3 TOPO cloning reaction 
The blunt-end PCR for hTCad was directionally cloned into the pENTRTM-TOPO vector and 
transformed into One Shot® chemically competent E. coli. 
Cloning was obtained using a 0.5:1 or 2:1 molar ratio of PCR product and TOPO vector. 
This equals 5-10 ng of a 2 kb PCR product. The TOPO Cloning reaction was performed as 
described in the manual. 
4.0 µl of the PCR product (1.33ng/µl), 1.0 µl of the salt solution and 1.0 µl of the TOPO® 
vector that is a topoisomerase І, were mixed gently and incubated for 5-30 min at room 
temperature to obtain sufficient amounts of colonies, which were put on ice afterwards or 
stored at -20˚C overnight.   
From this solution 2 µl was put into a vial of E. coli, mixed gently and incubated on ice for 5 
min. Then the cells were heat shock treated for 30 sec at 42˚C without shaking and 
immediately transferred to ice, added 250 µl of room tempered S.O.C. medium and 
incubated at 37˚C for 1 hour in horizontally position while shaken at 200 rpm. 
The cells were plated out on pre-warmed 10 cm LB (Luria-Bertani, blue/white selection) 
agar dishes containing 50µg/mL kanamycin. A volume of 50 µl and 200 µl from each 
transformation were spread on the agar dishes to ensure separately grown bacteria colonies, 
and the dishes were incubated overnight at 37˚C. 
The positive clones were analyzed by picking 5-10 single transformed (white) colonies and 
culturing them overnight in 5 ml LB medium containing 10 µl kanamycin (30 µg/µl). 
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The tubes were incubated at 37˚C overnight in horizontally position while shaken (200rpm). 
To extract and purify the high copy plasmid DNA from E.coli cultures the Plasmid MiniPrep 
(JETquick) kit was used. The procedure was performed according to manufacturer’s 
instructions.  
2.3.4 Miniprep (JETquick) 
A volume of 2 ml was removed from the bacteria suspension and centrifuged 13000rpm for 
5 min. The supernatant was discharged and the pellet was resolved in 250 µl G1 solution 
(provided in the kit) to a homogenous solution. From solution G2 250 µl was added for lysis 
of the cells. The liquids were mixed carefully without vortexing, and let stand 5 min at room 
temperature. Then 350 µl of solution G3 was added to neutralize the lyses solution and 
mixed carefully and centrifuged at 13000rpm for 10 min. The Jetquick spin column was 
placed in a 2 ml microfuge tube and the supernatant transferred from the centrifugation 
process to the column and centrifuged at 13000 rpm for 1 min. The flowthrough was 
discarded and 500 µl G4 solution was added to wash the column. Then the column was 
centrifuged at 13000 rpm for 1 min. The flowthrough was discarded and the column 
centrifuged again. The plasmid was eluted by placing the column into a clean 1.5 ml 
microfuge tube and 75 µl DEPC water was added to the middle of the column and then 
centrifuged 13000 rpm for 2 min. The elute was stored -20˚C. OD260 measurements were 
performed from the elute to calculate the concentration of high copy plasmid.  
2.3.5 Restriction enzyme digest 
To ensure that the cloning products were the correct ones, a restriction enzyme digest 
analysis was performed.  For the restriction enzyme digest, the restriction enzymes Not І 
(TAKARA BIO INC. Shiga, Japan) and Sal І (Promega, WI-USA) were chosen. Not І is a 0 
cutter and Sal І is a 1 cutter (cuts with 1636/1640pb, and the longest bp sequence is 501bp). 
This procedure was performed according to Manufacturers instruction, where 9 tubes 
containing 0.5 µl Sal І, 1 µl Not І, 3 µl plasmid DNA, 2 µl buffer D and 13.5 µl MQ water 
were mixed to a total volume of 20 µl. The 10th tube contained 3 µl of plasmid DNA, 2 µl 
buffer D, 15 µl MQ water but no enzymes. After incubation at 37˚C overnight, the samples 
were analyzed by agarose gel electrophoresis 1% (110 V, 90 min) to confirm the size of the 
PCR products. More DNA from positive clones was used in a new restriction enzyme digest 
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with bigger volumes. This was also analyzed by agarose gel electrophoresis. For the new 
restriction enzyme digest 10 µl buffer, 2 µl Not І, 2 µl Sal І and 10 µl DNA was mixed and 
the total reaction volume was 100 µl.  This was put in an incubator keeping 37˚C for 1-2 h, 
and afterwards analyzed by agarose gel electrophoresis 1% (100 V, 90 min). A match was 
found with one of the bands and the content of this bacterial suspension was chosen for 
further experiments.   
100 ml LD-medium was added 200 µl kanamycin (30 µg/mL) and 100 µl from the bacterial 
suspension. This was put in a shaker holding 37 ˚C, overnight. 
Plasmid DNA was extracted and purified from the gel by JETstar MaxiPrep procedure. The 
plasmid vectors obtained by MaxiPrep were control sequenced by MedProbe AS (Norway) 
in both forward and reverse direction by using M13 forward 
(GTAAAACGACGGCCAGTC) and reverse (CAGGAAACAGCTATGAC) primers 
respectively. All base pairs in the insert were analyzed to assess if any mutations had 
occurred in the DNA during cloning process. This sequencing showed uncertain regions in 
one area of the DNA. These regions had to be sequenced one more time to assure that no 
mutations had occurred. This uncertain region was localized in the middle of the DNA. 
A primer that covered this area was found after analyzing the base pair region with different 
primers that would cut and cover the desired area of the DNA. 
The plasmid vectors were control sequenced one more time by MedProbe (Norway) with 
hTCAD-F primer (Eurogentec, Seraing, Belgum) (5`-GTT-GGC-AAG-GTA-GTC-G-3`) to 
survey uncertain regions in middle of the DNA sequence.   
2.3.6 Maxiprep (JETstar) 
A column was put in the rack with a collective tube underneath and 30 ml of solution E4 was 
added to equilibrate the column. The solution was let to pass through the column without 
adding any pressure. 
The bacterial suspension was transferred to a plastic tube and centrifuged 5000rpm at 4˚C 
for 10 min. All traces of medium were carefully removed and 10 ml of solution E1 was 
added, the pellet was resolved to a homogeneous suspension and transferred to a glass tube. 
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To lysis the bacteria cells 10 ml of solution E2 was added and mixed carefully, not vortexed, 
and let stand for 5 min at room temperature.      
To neutralize the lysis process 10 ml of solution E3 was added, mixed immediately to a 
homogenous solution was obtained, but not vortexed. The solution was centrifuged at 13000 
rpm for 10 min at room temperature.  
To load the column the supernatant from the last centrifugation was applied and the lysate 
allowed to migrate through by gravity flow. The column was washed with 60 ml of solution 
E5 and the plasmid eluted with addition of 15 ml of solution E6. A clean tube was placed 
underneath the column. The remaining solution was not forced through the column. Plasmid 
precipitation was performed by adding 10.5 ml isopropanol and centrifuged at 13000 rpm at 
4˚C for 30 min. The supernatant was removed and the plasmid DNA washed with 70 % 
ethanol. The column was re-centrifuged 13000rpm for 30 min. The pellet was air dried for 
10 min, re-dissolved in 100 µl MQ water and transferred to an Eppendorf tube. The tube was 
washed one more time with 100 µl MQ water and this volume was added to the tube.  
The concentration was measured by OD492 nm and thereafter calculated. 
A new bacterial culture in liquid media was made for storage. 1.5 ml of the bacterial 
suspension was added 0.5 ml glycerol 60% and stored at -70 ˚C.   
2.3.7 Standard curve 
For the purpose of quantification, a standard curve was systematically constructed from a 
serial 10-fold dilution of the cDNA generated during the TOPO-cloning reaction in DEPC-
treated water.  The concentrations used were in the range between 100 pg to 0.001 fg. The 
concentration used for further PCR was 0.01 pg. This concentration corresponded to the 
linear region and thus the number of cycles found in earlier T-cadherin experiments. 
PCR was performed as for qRT-PCR of AR1 and AR2, using a LightCycler (Roche 
Diagnostics, Mannheim, Germany). The assay was performed in duplicate. 
The primers used were hTCAD-F (5’-GTT-GGC-AAG-GTA-GTC-G-3’) and hTCAD-R (5’-
CGATGTAGGGGCCTTC-3’), both from Eurogentec (Seraing, Belgum).  
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A straight line was fitted to the data created from different concentrations of the serial 
dilution of T-cadherin cDNA. Linear regression of T-cad concentrations created a slope of -
2.686 (r = -0.98) and indicated that the standard curve was valid and could be used for T-
cadherin quantification.  
The program used for PCR was initiated with a denaturizing step at 95˚C for 10 min. The 
temperature cycling was then initiated and consisted of denaturizing at 95˚C for 10 sec, 
hybridization at 55˚C for RPL27 and 60˚C for hTCad for 3 sec and elongation at 72˚C for 10 
sec. A final hold for 30 sec at 40˚C was obtained. Approximately 45 cycles were performed.       
2.3.8 1 Kb Plus DNA Ladder 
The 1 Kb Plus DNA Ladder originated from Invitrogen Life Technologies (Carlsbad, CA) 
and the concentration was 1 µg/µl. It was used for verification of PCR product on agarose 
gel stained with ethidium bromide, electrophoresis 80-100V for approximately 90 min. The 
1650-bp band contained approximately 8 % of the mass applied to the gel and when the size 
of the bands were compared to dilution lines of the ladder, the concentration could be 
calculated.   
2.4 Scanning tissue panels for occurrence of T-cadherin receptor 
A selection of tissues was scanned to gain knowledge about distribution of T-cadherin 
receptors in the body. The same human tissue panel was previously analyzed for the 
expression of adiponectin receptor 1 and 2.    
This tissue panel was composed of tissue samples from adipose tissue, adrenal gland, bone 
marrow, brain whole, fetal brain, fetal liver, heart, kidney, liver, lunge whole, placenta, 
prostate, salivary gland, skeletal muscle, testis, thymus, thyroid gland, trachea, uterus and 
spinal cord. Measured values were normalized by use of RPL27 as an internal control. 
Duplicate test of these tissues were analyzed. 
RNA from a selection of tissues like BeWo (placenta trophoblasts), THLE (liver), Raji and 
Ramos (B-cells), THP-1 (control-monocytt and PMA treated-macrophage), U937 (control-
monocytt and PMA treated-macrophage), Jurkat (T-cells) and SGBS cells (undifferentiated 
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and differentiated) were isolated with TRIzol, the concentration was measured with OD and 
RT Taqman Reverse transcriptase was performed as the procedure described for HepG2 
cells.  
cDNA from a previous study with myotubes from 8 type 2 diabetic and 8 obese donors was 
analyzed for T-cadherin as well as AR1 and AR2 expression in human myotubes. 
Differentiated myotubes (4d) had been pre-incubated with bovine serum albumin (BSA) and 
different FAs in 100µM concentration; oleic acid (OA), eicosapentanoic acid (EPA) and 
tetradecylthioacetic acid (TTA) for 4 days, before harvested for RNA isolation and cDNA 
synthesis. cDNA from type 2 diabetic and obese donors was pooled into their respective 
groups and the average effect of different pre-incubations was analyzed to investigate the 
effect of the different FAs on T-cad receptor and AR1 and AR2 expression. Duplicate test of 
these tissues were analyzed. 
Different cDNA was analyzed by PCR with a LightCycler (Roche Diagnostics, Mannheim, 
Germany). RPL27 was used as the housekeeping gene. 
The program used for PCR analyzes was initiated by a denaturizing step at 95˚C for 10 min, 
the temperature cycling was then initiated and consisted of denaturizing at 95˚C for 10 sec, 
hybridization at 55˚C for RPL27 and 60˚C for hTCad for 3 sec and elongation at 72˚C for 10 
sec. A final hold for 30 sec at 40˚C was obtained. Approximately 45 cycles were performed.  
2.5 Skeletal muscle cells 
Primary muscle cells from biopsies:  
Donor LD 16; male, 33 years old, fasting blood glucose levels 5.5 mM, BMI 22.99.  
Donor LD 29; male, 35 years old, fasting blood glucose levels 4.9 mM, BMI 19.62.  
Donor LD 30; male, 36 years old, fasting blood glucose levels 5.0 mM, BMI 26.20. 
2.5.1 Seeding out muscle cells 
Cryogenically frozen cells were quickly thawed. The cell suspension was then transferred to 
a 50 ml falcon tube containing M1-medium. The cyro-tube was washed with the same M1-
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medium twice to assure that all the cells were transferred. The suspension was then mixed 
thoroughly before the cells were seeded out on 96-well plates by an 8-channel multi pipette 
(100 µl per well inside 80 wells). CellBIND® plates were chosen to improve cell 
attachment. Cell density was targeted to approximately 3000-6000 cells/cm². 
2.5.2 Growing and differentiation of primary cells into myotubes 
The primary cells were grown in an incubator maintaining constant temperature at 37ºC and 
5 % CO2 enriched atmosphere. The flasks contained approximately 1 ml medium per 10 cm2. 
After 24 h of incubation the initial medium was changed to M2-medium. The cells were then 
proliferated until reaching 70-80 % confluence. The medium was then switched to M3, thus 
initiating differentiation of the cells into myotubes. The myotube poly-nucleated structures 
formed from fusion of precursor cells were to be apparent 1-2 day(s) after initiating 
differentiation. The M3-medium was changed every second day. The myotubes were usually 
given preincubations (if any) dissolved in M3-medium from day 4 after initiation of 
differentiation. The cells were visually inspected during growth and differentiation to see 
that they developed as intended. The myotubes were harvested between days 4 to 10 after 
initiating of differentiation.  
Experiments with full length adiponectin 
The significance of adding serum to the pre-incubation medium was tested in the preliminary 
experiment. The medium added to half of the wells contained 2 % fetal calf serum (FCS) and 
the remaining wells did not receive any FCS in their media. The effect of adiponectin was 
also assessed by adding 0.5 µg/mL full-length adiponectin into the medium of half of the 
two serum incubations. The medium added to the acute incubation was serum deficient. 
Only one experiment was performed with full-length adiponectin.  
 
2.5.3 Fatty acid oxidation  
Medium was changed from M3-medium to experimental medium at different time intervals. 
Four wells were given same incubation sufficient for each different experimental condition, 
to get a good estimate of the mean 14CO2 generated and trapped during a time interval. Four 
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wells received just regular M3-medium as a control. The effect of incubating cells with 
adiponectin on FA oxidation was investigated. The amount of FA oxidation was measured 
by using a CO2 trapping device (fig 2.1).  
For each time interval the cells received medium containing different amount of adiponectin. 
The first experiment was performed with full-length adiponectin (flAdn), later experiments 
were performed with globular (gAdn) and trimer type (tAdn). The cells were incubated for 4 
h with radioactive oleic acid medium, followed by protein content, acid soluble metabolites, 
cell associated metabolites and CO2 amount measurements. Wells receiving acute incubation 
were incubated with adiponectin in the medium during the 4 h long trapping period. The 
remaining cells were investigated for accumulated adiponectin effect on FA oxidation, and 
no adiponectin was added to the medium during trapping period. 
The medium was devoid of H2CO3 buffer. The cells were washed with DPBS (with Calcium- 
and Magnesium Chloride) containing 20mM Hepes buffer before they were put inside the 
airtight CO2-trapping device. A silicon mat was put between the two plates before they were 
sealed in the trapper device.  The filter plate wells were pre-wetted with 25 µl 1 M NaOH 
shortly before they were sealed.  
Acutely, the cells were given medium containing [1-14C]oleic acid, concentration 1 µCi/mL 
(50µM) and total FA concentration 18.2 nmol/mL. The device was put into an incubator 
maintaining 37ºC for 4 h.  
After incubation, the cell medium was transferred to another plate and the cell plate was 
washed twice with 200 µl PBS, and then 0.05 M NaOH was added and the plates were 
covered with plastic and cooled at -20ºC, if not processed right away.  
The cells were assayed for protein, cell-associated radiolabel (CAR) and acid soluble 
metabolites (ASM). The wells were added Microscint-O or Optiphase Supermix, the plate 
was sealed on top with translucent plastic adhesive cover slip and let stand for 24 h. All 
samples were analyzed in the Microbeta trilux® from Wallac, either in opaque 96 wells filter 
plates or in opaque 96 wells plates with transparent base plate. 
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Figure 2.1 Equipment for CO2 trapping and the principle behind the method.  
 
2.5.4 Measurement of protein  
1 part of the Bio-Rad protein dye was diluted with 4 parts of milliQ water. A volume of 50 
µl from each well of the cell lysate was transferred to a new 96 wells plate. 50 µl 0.05 M 
NaOH was added to the last row of wells to assess bias. 200 µl of the diluted protein 
reagents was added to each well. Bobbles were removed to avoid measurement interfere. 
Plates were let stand for 5 min and measured at 590 nm using a spectrophotometric 
microplate reader (Titertek Multiscan Plus (MK-ІІ), LabSystems, Helsinki). The linear range 
of the assay for BSA is 0.2 to 0.9 mg/mL. For the purpose of quantification, a standard curve 
was used to calculate the amount of protein.  
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2.5.5 Cell-associated radiolabel (CAR) 
A volume of 100 µl of cell lysate was removed from each well and transferred into a new 
opaque 96-well plate with transparent base plate. Scintillation fluid 200 µl was added. The 
plates were kept for 24 h in room temperature before measuring in the Microbeta trilux®. 
2.5.6 Acid soluble metabolites (ASM)    
A volume of 25 µl from the cell medium of each well was added to a 96-well plate with 
conic bottom. As a control, 25 µl of the medium used in the experiment was added to the last 
row. 25 µl BSA 6 % was added to each well. Liquids were well mixed by use of a pipette, 
before adding 250 µl cold perchloric acid (PCA) 1 M. The liquids were let stand 30-60 min 
at 4ºC, and then spun down at 2800 rpm equaling 1480 G (Megafuge 1.0R) for 15 min at 
4ºC. 
A volume of 100 µl of supernatant from each well was removed and transferred to an opaque 
96-well plate. Scintillation fluid 200 µl was added. The plates were let standing for 24 h 
before measuring in the Microbeta trilux®. 
2.5.7 Resolved acid soluble metabolites  
The rest of the supernatant from plates used for ASM measurement was removed. 200 µl 
SDS-NaOH solution was added to each well. Plates were then covered with plastic and left 
at room temperature until resolved. Then 100µl was transferred to an opaque 96-well plate 
and 200 µl scintillation liquid added. The plates were let standing for approximately 24 h 
before measuring in the Microbeta trilux®. 
2.6 Validation of the CO2 trapping method  
The CO2 trapping method was verified with the use of Na14CO3 counted with scintillation 
fluid (Ophtiphase supermix, Perkin Elmer, Shelton, CT, USA) in Microbeta trilux®. The 
aim was to find the most optimal conditions for measuring the actual activity in 
disintegrations per minute (DPM).   
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To verify the use of the Microbeta trilux® and the change in 96 well filter plates from “deep 
wells” (300 µl) to “shallow wells” (75 µl), the values of the actual activity in DPM from the 
multi-well experiment was compared with the efficacy of measurements in single tubes.  The 
effect of pH in this experiment was tested out with diluting the radioactive solution added to 
the wet wells from 1 M to 0.1 M NaOH. The dry wells were let to dry for 24 h on a warm 
plate. Then the scintillation fluid was added and the plates were counted. The plates were 
counted every day for 5 days to see if there is a difference in counting efficacy if the plates 
are left for a while before counting (due to circulation). 
6 ml 1 M NaOH was added 6.6 µl Na14CO3 (1 mCi/mL, final concentration 1 µCi/mL). 25 µl 
of this solution was added to wells and to counting tubes. The solution was added to every 
second well to avoid contamination of the counting results in the neighboring wells.  Both 
deep and shallow wells were counted when wet and one parallel of each after let to dry 
overnight.     
The scintillation fluid was diluted with water in the ratios 1:0, 2:1, 1:1 and 2:3. 50 µl was 
added to the wet shallow wells, 200 µl was added to the wet deep wells, 75 µl was added to 
the shallow dry wells and 300 µl was added to the deep dry wells. 
In a different experiment, isoplates with transparent base plate were used, and filters cut out 
and fitted in the wells. These filters were added the same amount of radioactive solution, but 
only 50 µl scintillation fluid and was counted on the cell lysat program (counted from both 
sides). Some of the wells without filters were added radioactive oleic acid (1 µCi/mL) and 
the same amount of scintillation fluid. 
These results were compared with shallow filter plates, one with a transparent plastic cover 
and one with a white plastic covering the back of the plate.    
(The results from these experiments are not shown). 
2.7 Statistical analysis  
All data from experiments performed more than three times were analyzed by paired t-test, 
assuming normal, two-tailed distribution of investigational variables. Average values for 
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each measurement were added standard error of the mean for experiments performed less 
than three times. 
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3. Results 
3.1 Incubation of HepG2 cells with fatty acids 
The natural fatty acids (FAs) tested have fasting physiological plasma concentrations 
between 10 and 400 µM (21). We therefore incubated HepG2 cells with either 50, 100 or 
200 µM of the different natural FAs as well as TTA, TTTA and αTTA, to assess potential 
concentration effect on AR1 and AR2 mRNA expression. Results are shown in figures 3.1-4. 
Saturated fatty acids are known to induce insulin resistance more than unsaturated fatty 
acids. The physiological concentrations used for the saturated FA were also chosen for the 
Thia-FA so the effects on AR expression could be compared. 
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Figure 3.1 HepG2 cells incubated with fatty acids for 24 h before analyzed for 
content of adiponectin receptor 1 mRNA by RT-PCR. The fatty acids used were 
bovine serum albumin (BSA, essentially FA free) as a control, lauric acid (LaA, 
12:0), myristic acid (MA, 14:0) and stearic acid (StA, 18:0) in 50 µM, 100 µM and 
200 µM concentrations. Values are normalized with BSA as 100 %. Values are the 
mean of four independent experiments presented as mean ± S.E.M (bars), n = 4. 
Asterisk (*) indicates significant changes (P≤0.05, paired t-test)  
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Expression of AR1 in HepG2 cells was significantly decreased after pre-incubation with 
LaA (50, 200 µM) (P=0.008 and 0.048 respectively), MA (50 µM) (P=0.006) and StA (50, 
200 µM) (P=0.003 and 0.034, respectively).  
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Figure 3.2 HepG2 cells incubated with fatty acids for 24 h before analyzed for 
content of adiponectin receptor 1 mRNA by RT-PCR. The fatty acids used were 
bovine serum albumin (BSA, essentially FA free) as a control, heptadecanoic acid 
(HepA, 17:0), tetradecylthioacetic acid (TTA, C2S14:0), triple TTA (TTTA) and 
alphamethylTTA (αTTA) in 50 µM, 100 µM and 200 µM concentrations. The values 
were normalized with BSA as 100 %. Values are the mean of four independent 
experiments presented as mean ± S.E.M (bars), n = 4. Asterisk (*) indicates 
significant changes (P≤0.05, paired t-test).  
 
Figure 3.2 shows that expression of AR1 mRNA in HepG2 cells was significantly decreased 
after pre-incubation with HepA (50 µM) (P=0.045).  
The FA analogs TTA, TTTA and αTTA in concentration 50, 100 and 200 µM showed no 
significant reduction in adiponectin receptor 1 mRNA in these experiments.  
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Adiponectin receptor 2 (AR2) mRNA related to fatty acids 
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Figure 3.3 HepG2 cells were incubated with fatty acids for 24 h before 
analyzed for expression of adiponectin receptor 2 mRNA by RT-PCR. The 
fatty acids used were bovine serum albumin (BSA, essentially FA free) as a 
control, lauric acid (LaA, 12:0), myristic acid (MA, 14:0) and stearic acid (StA, 18:0) 
in 50 µM, 100 µM and 200 µM concentrations. Values are normalized with BSA as 
100 %. Values are the mean of four independent experiments presented as mean 
± S.E.M (bars), n = 4. Asterisk (*) indicates significant changes (P≤0.05, paired t-
test).  
 
Figure 3.3 shows that expression of AR2 mRNA in HepG2 cells was significantly decreased 
after pre-incubation with StA (50 µM) (P=0.008). Other FAs showed no significant changes 
in mRNA expression compared to BSA control.  
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Figure 3.4 HepG2 cells incubated with fatty acids for 24 h before analyzed for 
expression of adiponectin receptor 2 mRNA by RT-PCR. The fatty acids used 
were bovine serum albumin (BSA, essentially FA free) as a control, heptadecanoic 
acid (HepA, 17:0), tetradecylthioacetic acid (TTA, C2S14:0), triple TTA (TTTA) and 
alphamethylTTA (αTTA) in 50 µM, 100 µM and 200 µM concentrations. The values 
were normalized with BSA as 100 %. Values are the mean of four independent 
experiments presented as mean ± S.E.M (bars), n = 4. Asterisk (*) indicates 
significant changes (P≤0.05, paired t-test).  
 
 
Figure 3.4 shows that no significant reduction in adiponectin receptor 2 mRNA was 
observed in experiments with HepA and TTA, TTTA and αTTA FA analogs in 
concentrations 50, 100 and 200 µM. 
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3.1.1 Lactate dehydrogenase (LDH)-activity in cell culture media 
For some of the FA incubations, the HepG2 cells changed appearance when they were 
investigated in the microscope compared to the cells incubated with BSA, where the cells 
kept their natural appearance. Cells clustered together and did not stretch over the surface in 
the same way as for BSA incubated cells. The LDH was measured in the media after 24 h of 
pre-incubation with FAs, and related to total LDH amount after complete cell lysis. 
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Figure 3.5 Leakage of LDH into media as percent of total release after 
incubating HepG2 cells with fatty acids. The fatty acids used were bovine 
serum albumin (BSA, essentially FA free) as a control, lauric acid (LaA, 12:0), 
myristic acid (MA, 14:0), heptadecanoic acid (HepA, 17:0), stearic acid (StA, 18:0), 
tetradecylthioacetic acid (TTA, C2S14:0), alphamethylTTA (αTTA) and triple TTA 
(TTTA) in 50 µM, 100 µM and 200 µM concentrations.  Values are the mean of four 
independent experiments mean percentage ± S.E.M (bars), n = 4. * indicates 
significant changes in LDH values between 50µM BSA and other FAs present at 
50 µM, # indicates significant changes in LDH values between BSA 100 µM and 
other FAs present at 100 µM and † indicates significant changes in LDH values 
between 200 µM BSA and other FAs present at 200 µM, respectively (P≤0.05, 
paired t-test).  
 
Figure 3.5 shows that the long saturated FAs, HepA and StA, increases LDH release. More 
specifically, significant changes were found when comparing BSA 50 µM with; StA 50µM 
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(P= 0.049), LaA 50 µM (P= 0.007), HepA 50 µM (P= 0.040), BSA 100 µM with StA 100 
µM (P= 0.017) and BSA 200 µM with; MA 200 µM (P= 0.029) and StA 200 µM (P= 0.019). 
For all other FAs, there were no significant changes in LDH release.  
Significant dose dependent LDH elevations with increasing FA concentrations were also 
found when comparing different concentrations of the same FA. More specifically, there was 
a FA concentration-dependent LDH increase from MA 50 µM to MA 200 µM (P= 0.005), 
from MA 100 µM to MA 200 µM (P= 0.029), from StA 50 µM to StA 200µM (P= 0.037), 
from StA 100 µM to StA 200 µM (P= 0.029), from LaA 50 µM to LaA 100 µM (P= 0.011), 
from LaA 50 µM to LaA 200 µM (P= 0.007), from LaA 100µM to LaA 200µM (P= 0.012), 
from HepA 100µM to HepA 200 µM (P= 0.047) and from aTTA 50 µM to aTTA 100 µM 
(P= 0.006).  
3.2 Quantification of T-cadherin mRNA 
3.2.1 Primer design and testing 
Primers suited for qRT-PCR (product length< 280 bp) targeting the human T-cadherin 
coding region were designed using NCBI Sequence Viewer and the sequence CDS 121-2262 
bp (gi: 61676095, gi for CDS: 4502719). The primer pair was initially tested in a Light 
Cycler instrument and cDNA from HepG2 cells, synthesized with reverse transcriptase from 
isolated total RNA, was used as a template. The PCR product was analyzed by agarose gel 
(1%) electrophoresis and several unspecific bands appeared. To make the reaction conditions 
optimal, several parameters were changed. Different annealing temperatures (55˚C - 65˚C), 
annealing times (3-5 sec.) and MgCl2 concentrations (1.6–3.2 µl) were tested without 
improving the specificity of the reaction.  
Therefore, a new set of primers was designed and tested. Still unspecific bands showed up 
when the PCR product was analyzed on an agarose gel (1%). Then, cDNA was tested from 
human heart tissue. The PCR reaction with human heart tissue cDNA template produced a 
single 280 bp band on an agarose gel, as showed in figure 3.6. Water was used as a negative 
control in all the tests.   
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Figure 3.6 Testing of candidate primer pairs for use in qRT-PCR. PCR product 
of T-cadherin (280 bp) and negative control (water) were run on agarose gel (1 %). 
SD = 1 kb Plus ladder    
 
3.2.2 Cloning of the protein encoding region of T-cadherin for use as a positive control 
and standard curve in qRT-PCR 
In the second step of establishing a qRT-PCR method for the measurement of T-cadherin, 
the complete protein coding region for this gene was cloned. Verified DNA (cut out from 
plasmid DNA by restriction enzymes) from the clone was used as positive control and serial 
diluted standard curves in qRT-PCR with the primer pair hTCAD-R and hTCAD-F. Blunt 
end-products were cloned into the pENTR/D-TOPO vector and transformed into E. coli 
bacteria. 
The plasmids were added restriction enzymes (Sal І and Not І enzymes) to analyze and 
identify which plasmid contained the complete protein coding region inserted in the correct 
direction.  
After analysis through agarose gel electrophoresis, one clone of a total of 10 clones was 
identified yielding the predicted bands 1652 bp (1636 insert and 16 bp) and all vector (2580 
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bp and (501 bp-16 bp)) 3069 bp (sample number 3 figure 3.7). This restriction enzyme 
analysis was performed as a control of both the size of the PCR-product and to exclude 
confusion with super-coiled plasmid DNA.  
The complete coding region inserted in the cloned plasmid was control sequenced twice by 
MedProbe (Norway), and the resulting sequence was verified by alignment (BLAST) with 
the original GENEBANK mRNA sequences.  
 
bp
3000
2000
1650
1000
+SD
3069
1652
-
 
Figure 3.7 Cloning of complete coding region of T-cadherin receptor, for use 
as a control and standard in qRT-PCR. Plasmid DNA (Miniprep) incubated with 
the Not I and Sal I restriction enzymes and then analyzed by agarose gel 
electrophoresis (1 %). SD = 1 kb Plus ladder 
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3.3 Expression of T-cadherin receptor  
Tissue expression of T-cad mRNA 
0,00E+00
5,00E-14
1,00E-13
1,50E-13
2,00E-13
2,50E-13
3,00E-13
3,50E-13
4,00E-13
Fe
ta
l b
ra
in
H
ea
rt
U
te
ru
s
Lu
ng
, w
ho
le
Sk
.m
us
cl
e
B
ra
in
, w
ho
le
S
pi
na
l c
or
d
P
ro
st
at
e
Te
st
is
P
la
ce
nt
a
Th
yr
oi
d 
gl
an
d
K
id
ne
y
Tr
ac
he
a
A
di
po
se
 ti
ss
ue
S
ta
nd
ar
d
Th
ym
us
A
dr
en
al
 g
la
nd
Fe
ta
l li
ve
r
S
al
iv
ar
y 
gl
an
d
liv
er
B
on
e 
m
ar
ro
w
w
at
er
C
al
cu
la
te
d 
co
nc
. T
-c
a d
 
Figure 3.8. Expression of T-cadherin mRNA in a tissue panel. mRNA values 
were measured by RT-PCR and normalized by use of RPL27 as an internal 
control. The calculated values were measured with the use of a standard curve for 
T-cadherin receptor (n=2). 
 
Figure 3.8 shows that the distribution of T-cadherin receptor mRNA in the body varies 
substantially, where fetal brain exhibited highest expression, brain (whole) and spinal cord 
were moderately expressed and liver and bone marrow were barely detectable. Fetal brain 
contained a 1000-fold more T-cadherin than liver.   
 
Expression of T-cad in different cell types 
cDNA from a selection of cells was also analyzed for expression of T-cad receptor. cDNA 
from U937 control (monocytes) was first used to generate T-cadherin receptor DNA for the 
cloning process. cDNA was then analyzed by gel electrophoresis, and small amounts of T-
cad in these cells were found. Other cells analyzed were SGBS cells undifferentiated and 
differentiated (day 1 and day 19) (stromal cell fraction of subcutaneous adipose tissue of an 
infant with Simpson Golabi Behmel syndrome), cDNA from experiments performed by 
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Andreas J Wensaas with cultured and differentiated primary human muscle cells (myotubes), 
and cDNA from BeWo (placental trophoblast cell-line), THLE (liver cell-line), Raji and 
Ramos (B cell-lines), Jurkat (T cell-line), THP-1 (monocyte cell line), PMA treated THP-1 
(differentiated into macrophages)) and U937 (monocyte cell line), PMA treated U937 
(macrophages).  
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Figure 3.9 Expression of T-cadherin receptor mRNA in cells and selected 
malign lymphoid cell lines. The cDNA was analyzed by RT-PCR and quantified 
by use of a standard curve. The measured amount of T-cadherin mRNA is the 
average of two measurements (n=2). 
 
Figure 3.9 shows that the amounts of T-cadherin receptor mRNA in different cells varied 
greatly. Myotubes and adipose tissue (SGBS cells) expressed 1000-fold more T-cadherin 
receptor mRNA compared to Raji, Ramos and Jurkat.  
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Figure 3.10 Expression of T-cadherin receptor mRNA in myotubes from 8 
obese and 8 type 2-diabetic donors. The expression of T-cad was analyzed by 
RT-PCR and all measurements were normalized for housekeeping gene RPL27. 
The myotubes were incubated with bovine serum albumin (BSA) as a control, oleic 
acid (OA, (18:1, n-9)), eicosepentaenic acid (EPA, (20:5, n-3)) and 
tetradecylthioacetic acid (TTA (17:0, 3-thia)) at 100 µM concentration. (n=2)     
 
Figure 3.10 shows that oleic acid and eicosapentaenoic acid may decrease expression of T-
cad by 9 and 11% respectively, compared to BSA in myotubes derived from type 2-diabetic 
donors. The apparent effect tetradecylthioacetic acid was an increase of 13 % compared to 
BSA. Oleic acid, eicosapentaenic acid and tetradecylthioacetic acid apparently decreased 
expression of T-cad by 7, 18 and 5 % respectively compared to BSA in myotubes derived 
from obese.  
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Figure 3.11 Expression of AR1 mRNA in myotubes from 8 obese and 8 type 2 
diabetic donors. The expression of AR1 was analyzed by RT-PCR and all 
measurements were normalized for housekeeping gene RPL27. The myotubes 
were incubated with bovine serum albumin (BSA) as a control, oleic acid (OA, 
(18:1, n-9)), eicosepentaenic acid (EPA, (20:5, n-3)) and tetradecylthioacetic acid 
(TTA (17:0, 3-thia)) at 100 µM concentration. (n=2)      
 
Figure 3.11 shows that eicosapentaenic acid and tetradecylthioacetic acid apparently 
decreased the expression of AR1 by 9 and 10 % respectively compared to BSA in myotubes 
derived from type 2-diabetic donors.  
 48 
AR2 mRNA expression 
0
0,00001
0,00002
0,00003
BSA OA EPA TTA
Different fatty acid treatment
AR
2/
R
PL
27
T2D
Obese
 
Figure 3.12 Expression of AR2 mRNA in myotubes from 8 obese and 8 type 2 
diabetic donors. The expression of AR2 was analyzed by RT-PCR and all 
measurements were normalized for housekeeping gene RPL27. The myotubes 
were incubated with bovine serum albumin (BSA) as a control, oleic acid (OA, 
(18:1, n-9)), eicosepentaenic acid (EPA, (20:5, n-3)) and tetradecylthioacetic acid 
(TTA (17:0, 3-thia)) at 100 µM concentration. (n=2) 
 
Figure 3.12 shows that oleic acid, eicosapentaenic acid and tetradecylthioacetic acid 
apparently do not affect AR2 expression compared to BSA in myotubes derived from type 2-
diabetic or obese donors. 
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3.4 Effect of adiponectin on human myotubes 
3.4.1 Experiments with full-length adiponectin 
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Figure 3.13 Effect of full-length adiponectin on CO2 production after 
incubation with radioactive oleic acid for 4 h. Differentiated myotubes were 
preincubated in media with or without adiponectin (0.5 µg/mL) and serum (2 %) for 
2, 4, 24 or 48 h. Afterwards the myotubes were incubated for 4 h with [1-14C]oleic 
acid (1 µCi/mL 50 µM), L-carnitine (1 mM) and glucose (5 mM). The media added 
to the acute incubation were added adiponectin during the 4 hour incubation 
period. Radiolabeled CO2 was trapped and quantified. The means ± standard 
deviation is given as absolute quantities of the parallels (n=4). 
 
Figure 3.13 show that there is a possible decrease in oleic acid oxidation for the longest pre-
incubation periods for cells grown in serum and adiponectin deficient medium, compared to 
acute incubation. Measured oleic acid oxidation seemed to decrease after extensive pre-
incubation periods for cells pre-incubated with adiponectin containing medium deficit of 
serum. There seemed to be no increased effect of adiponectin related to FA oxidation on 
cells incubated with adiponectin and serum containing media, Pre-incubating cells with 
 50 
medium containing serum and no adiponectin, seemed to have minor effect on oleic acid 
oxidation. 
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Figure 3.14 Effect of full-length adiponectin and serum on cell mediated ASM 
after incubation with radioactive oleic acid for 4 h. Differentiated myotubes 
were preincubated in media with or without adiponectin (0.5 µg/mL) and serum (2 
%) for 2, 4, 24 or 48 h. Afterwards the myotubes were incubated for 4 h with [1-
14C]oleic acid (1 µCi/mL 50 µM), L-carnitine (1 mM) and glucose (5 mM). The 
media added to the acute incubation were added adiponectin during the 4 hour 
incubation period.  The means ± standard deviation is given as absolute quantities 
of the 4 parallels of each incubation. 
 
Figure 3.14 shows that cells pre-incubated with medium containing both serum and 
adiponectin seemed to increase oleic acid oxidation. The same tendency was seen for cells 
pre-incubated with medium containing only serum. For cells pre-incubated with medium 
containing  adiponectin only and cells pre-incubated with plain medium, there seemed to be 
a tendency for increased oleic acid oxidation with shorter pre-incubation periods. 
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Figure 3.15 Effect of full-length adiponectin and serum on cell-associated 
radiolabel (CAR) after incubation with radioactive oleic acid for 4 h. 
Differentiated myotubes were preincubated in media with or without adiponectin 
(0.5 µg/mL) and serum (2 %) for 2, 4, 24 or 48 h. Afterwards the myotubes were 
incubated for 4 h with [1-14C]oleic acid (1 µCi/mL 50 µM), L-carnitine (1 mM) and 
glucose (5 mM). The media added to the acute incubation were added adiponectin 
during the 4 hour incubation period.  The means ± standard deviation is given as 
absolute quantities of the 4 parallels of each incubation. 
 
Figure 3.15 shows no clear tendency towards an effect on cell-associated radiolabel 
measurements when adiponectin is added to the pre-incubation or incubation media. 
Regardless of adiponectin content, cells incubated with serum deficient medium seemed to 
increase cell-associated radiolabel measurements after a 2-hour pre-incubation period and 
acute incubation with adiponectin.  
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3.4.2 Experiments with globular adiponectin  
Experiments were performed with four different pre-incubation time intervals and different 
concentrations of adiponectin (figure 3.16 to 3.21). In the first experiments myotubes were 
pre-incubated with gAdn for 72, 48, and 24 h or had adiponectin added to the media only 
during the 4 hour incubation with oleic acid. In the second experiment with gAdn myotubes 
were pre-incubated for 24, 4 and 2 h or had adiponectin added to the media only during the 4 
hour incubation with oleic acid.  
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Figure 3.16 Effect of globular adiponectin on CO2 measurements after 
incubation with radioactive oleic acid for 4 h. Differentiated myotubes were 
added media containing various amounts of adiponectin at defined time intervals. 
The experiment was performed by preincubating the cells for 24-, 48- or 72 h with 
different media and incubating the cells for 4 h with [1-14C]oleic acid (1 µCi/mL, 50 
µM), 0.2 % Fetal Calf Serum (FCS), L-carnitine (1 mM) and glucose (5 mM). The 
adiponectin concentrations used were 0.1, 0.5, 1 and 2 µg/mL. The media for the 
acute incubation were added adiponectin during the 4 hour incubation period. 
Radiolabeled CO2 was trapped and quantified. The means ± SEM is given as 
absolute quantities of the 8 parallels. 
 
For cells pre-incubated with the lowest adiponectin concentrations there seemed to be a 
tendency for an increase in oleic acid oxidation with increasing pre-incubation time (figure 
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3.16). There seemed to be a tendency for a decreased OA oxidation when pre-incubating 
cells in higher concentrations of adiponectin. However, none of the measured changes in 
CO2 were statistically significant.  
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Figure 3.17 Effect of globular adiponectin on acid soluble metabolites (ASM) 
after incubation with radioactive oleic acid for 4 h. Differentiated myotubes 
were added media containing various amounts of adiponectin at defined time 
intervals. The experiment was performed by pre-incubating the cells for 24, 48 or 
72 h with different media and incubating the cells for 4 h with [1-14C]oleic acid (1 
µCi/mL, 50 µM), 0.2 % Fetal Calf Serum (FCS), L-carnitine (1 mM) and glucose (5 
mM). The adiponectin concentrations used were 0.1, 0.5, 1 and 2 µg/mL. The 
media added to the acute incubation were added adiponectin during the 4 hour 
incubation period. The means ± SEM is given as absolute quantities of the 8 
parallels. 
 
Figure 3.17 shows that the standard deviations for some of the ASM measurements are 
relatively high and therefore no conclusions regarding an effect of gAdn can be drawn based 
on these results.  
The next experiment that was performed with globular adiponectin, shorter time intervals 
were chosen; 24 h, 4 h, 2 h and acute incubation  with adiponectin. Lower doses of 
adiponectin were used; 0, 0.1, 0.25, 0.5 and 1 µg/mL. 
 55
 Cell-associated radiolabel (CAR) concentration 
0,00
10,00
20,00
30,00
40,00
50,00
60,00
70,00
80,00
90,00
100,00
72h 48h 24h 0,acute
Preincubation time in hours
nm
ol
/m
g 
pr
ot
ei
n
0
0,1
0,5
1
2
 
Figure 3.18 Effect of globular adiponectin on cell-associated radiolabel (CAR) 
measurement after incubation with radioactive oleic acid for 4 h. 
Differentiated myotubes were added media containing various amounts of 
adiponectin at defined time intervals. The experiment was performed by 
preincubating the cells for 24-, 48- or 72 h with different media and incubating the 
cells for 4 h with [1-14C]oleic acid (1 µCi/mL, 50 µM), 0.2 % Fetal Calf Serum 
(FCS), L-carnitine (1 mM) and glucose (5 mM). The adiponectin concentrations 
used were 0.1, 0.5, 1 and 2 µg/mL. The media for the acute incubation were added 
adiponectin during the 4 hour incubation period. The means ± S.E.M. is given as 
absolute quantities of the 8 parallels. 
 
For the cell-associated radiolabel (CAR) measurements there was a tendency towards an 
increased effect for the highest adiponectin concentrations used (figure 3.18). There seemed 
to be no increase in CAR measurements between the 72h- 48h- and the 24 hour pre-
incubation times. No changes in the measured CAR values were statistically significant. 
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Figure 3.19 Effect of globular adiponectin on CO2 measurements after 
incubation with radioactive oleic acid for 4 h. Differentiated myotubes were 
added media containing various amounts of adiponectin at defined time intervals. 
The experiment was performed by preincubating the cells for 2-, 4- or 24 h with 
different media and incubating the cells for 4 h with [1-14C]oleic acid (1 µCi/mL, 50 
µM), 0.2 % Fetal Calf Serum (FCS), L-carnitine (1 mM) and glucose (5 mM). The 
adiponectin concentrations used were 0.1, 0.25, 0.5 and 1 µg/mL. The media 
added to the acute incubation were added adiponectin during the 4 hour incubation 
period. Radiolabeled CO2 was trapped and quantified. The means ± S.E.M. is 
given as absolute quantities of the 8 parallels. 
 
Cells pre-incubated with adiponectin for 24 and 4 h showed a decrease in oleic acid 
oxidation with increasing concentration of adiponectin (figure 3.19). Adiponectin seemed to 
have a stimulating effect on the amount of fatty acid oxidation for the cells pre-incubated for 
2 h and acute incubation with adiponectin during the 4 hour incubation time. 
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Figure 3.20 Effect of globular adiponectin on acid soluble metabolites (ASM) 
after incubation with radioactive oleic acid for 4 h. Differentiated myotubes 
were pre-incubated in media containing 0, 0.1, 0.25, 0.5 and 1 µg/mL adiponectin 
and pre-incubated for 2, 4 or 24 h. The myotubes were later incubated for 4 h with 
[1-14C]oleic acid (1 µCi/mL, 50 µM), 0.2 % Fetal Calf Serum (FCS), L-carnitine (1 
mM) and glucose (5 mM). For the acute incubation, adiponectin was added to the 
medium during the 4 hour incubation period. The means ± SEM is given as 
absolute quantities of 8 parallels. 
 
There was no tendency for an effect of pre-incubating myotubes for 24 h with increasing 
concentration of gAdn, as shown in figure 3.20. For the 4 hour pre-incubation time a 
tendency for a decrease in measured ASM values with increasing concentration of gAdn was 
seen.  For the 2 hour pre-incubation and acute incubation with gAdn no tendency towards an 
increase in measured ASM values was observed that was related to the concentration of 
gAdn. 
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Figure 3.21 Effect of globular adiponectin on cell-associated radiolabel (CAR) 
after incubation with radioactive oleic acid for 4 h. Differentiated myotubes 
were added media containing varoius amounts of adiponectin at defined time 
intervals. The experiment was performed by preincubating the cells for 2-, 4- or 24 
h with different media and incubating the cells for 4 h with [1-14C]oleic acid (1 
µCi/mL, 50 µM), 0.2 % Fetal Calf Serum (FCS), L-carnitine (1 mM) and glucose (5 
mM). The adiponectin concentrations used were 0.1, 0.25, 0.5 and 1 µg/mL. The 
media added to the acute incubation were added adiponectin during the 4 hour 
incubation period. The means ± SEM is given as absolute quantities of the 8 
parallels. 
 
Measured values for the effect of gAdn on CAR measurements showed no clear tendencies 
towards an effect when comparing the pre-incubation times and concentrations of gAdn 
(figure 3.21).  
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Figure 3.22 Measure of Lactate Dehydrogenase (LDH) values in cell media 
after 4 h incubation with [1-14C]oleic acid (50 µM, 1 µCi/mL). Differentiated 
myotubes were added media containing different amounts of adiponectin at 
different time intervals. The experiment was performed by preincubating the cells 
for 24-, 48- or 72 h with different media and incubating the cells for 4 h with [1-
14C]oleic acid (1 µCi/mL, 50 µM), 0.2 % Fetal Calf Serum (FCS), L-carnitine (1 mM) 
and glucose (5 mM). The different adiponectin concentrations used were 0.1, 0.5, 
1 and 2 µg/mL. The media added to the acute incubation were added adiponectin 
during the 4 hour incubation period. 25 µl of cell medium from each well were 
diluted with 25 µl water and added 50 µl LDH-kit reagents. The plate was 
incubated for 10 min at 37ºC wrapped in aluminum foil. Amount LDH was 
measured with a spectrophotometer at 492 nm. The means ± S.E.M. is given as 
absolute quantities of the 4 parallels.  
 
In figure 3.22 the lactate dehydrogenase (LDH) measurements show no significant changes 
in measured values for different pre-incubation times and gAdn concentrations. 
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3.4.3 Experiments with trimer adiponectin  
Cells received trimer adiponectin at two different time intervals, 24 h and acute. Cells were 
then tested for oleic acid and glucose oxidation. 
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Figure 3.23 Effect of acute incubation with trimer adiponectin (tAdn) on 
glucose oxidation. Differentiated myotubes were incubated for 4 h with [6-
14C]glucose medium (1 µCi/mL, 100 µM) and 0.2 % Fetal Calf Serum (FCS). 
Trimer adiponectin concentrations in the medium were 0 (control), 0.1, 0.5, 1 and 5 
µg/mL. Radiolabeled CO2 was trapped and quantified. The means ± SEM is given 
as absolute quantities of 12 parallels (3 individual experiments with 4 parallels 
each). Asterisk (*) indicates significant change compared to control (p≤0.05, two-
tailed t-test). 
 
Trimer adiponectin significantly increased glucose oxidation (figure 3.23). A concentration 
of 1 µg/mL tAdn caused a 4-fold increase in glucose oxidation compared to control 
incubated without tAdn (P= 0.05). A significant increase in CO2 measurements was not 
found for the myotubes incubated with 5 µg/mL tAdn. 
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Figure 3.24 Effect of 24 h pre-incubation with trimer adiponectin (tAdn) on 
glucose oxidation.  Differentiated myotubes were pre-incubated 24 h with 
medium containing 0 (control), 0.1, 0.5, 1 and 5 µg/mL tAdn. The myotubes were 
then incubated for 4 h with [6-14C]glucose (1 µCi/mL, 100 µM) and 0.2 % Fetal Calf 
Serum (FCS). Radiolabeled CO2 was trapped and quantified. The means ± SEM is 
given as absolute quantities of 12 parallels (3 individual experiments with 4 
parallels each).  
 
As seen in figure 3.24 there was a tendency for a decrease in glucose oxidation with 
increasing amounts of tAdn in the pre-incubation medium, but no significant changes was 
observed.  
 62 
 CO2 concentration (oleic acid) 
0,00
0,40
0,80
1,20
1,60
2,00
0 0,1 0,5 1 5
Concentration og tAdn ug/ml
nm
ol
/m
g 
pr
ot
ei
n
 
Figure 3.25 Effect of acute incubation with trimer adiponectin (tAdn) on oleic 
acid oxidation. Differentiated myotubes were incubated for 4 h with [1-14C]oleic 
acid (1 µCi/mL, 50 µM), 0.2 % Fetal Calf Serum (FCS), L-carnitine (1 mM) and 
glucose (5 mM). Medium tAdn concentrations were 0 (control), 0.1, 0.5, 1 and 5 
µg/mL. Radiolabeled CO2 was trapped and quantified. The means ± SEM are 
given for 12 parallels (3 individual experiments with 4 parallels each).   
 
Figure 3.25 shows results of acute incubation with tAdn. There was no clear trend for a 
change in FA oxidation with increasing amounts of tAdn in the medium, compared to the 
myotubes incubated without tAdn.   
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Figure 3.26 Effect of 24 h pre-incubation with trimer adiponectin (tAdn) on 
oleic acid oxidation. Differentiated myotubes were pre-incubated 24 h with 
medium containing 0 (control), 0.1, 0.5, 1 and 5 µg/mL tAdn. The myotubes were 
then incubated for 4 h with [1-14C]oleic acid (1 µCi/mL, 50 µM), 0.2 % Fetal Calf 
Serum (FCS), L-carnitine (1 mM) and glucose (5 mM). Radiolabeled CO2 was 
trapped and quantified. The means ± SEM is given as absolute quantities of 12 
parallels (3 individual experiments with 4 parallels each). 
 
Figure 3.26 shows a trend towards increasing effects of tAdn on oleic acid oxidation. But no 
statistically significant changes were found.  
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Figure 3.27 Effect of acute incubation with trimer adiponectin (tAdn) on oleic 
acid oxidation and acid soluble metabolites. Differentiated myotubes were 
incubated for 4 h with [1-14C]oleic acid (1 µCi/mL, 50 µM), 0.2 % Fetal Calf Serum 
(FCS), L-carnitine (1 mM) and glucose (5 mM). Medium tAdn concentrations were 
0 (control), 0.1, 0.5, 1 and 5 µg/mL. The means ± SEM is given as absolute 
quantities of 12 parallels (3 individual experiments with 4 parallels each).  
 
Figure 3.27 shows a trend for tAdn to decrease oleic acid oxidation by approximately 50 % 
compared to cells not receiving adiponectin. The reduction in oleic acid oxidation were close 
to significant, p values being 0.06 for myotubes incubated with 0.1 and 1 µg/mL tAdn, 0.09 
with 0.5 µg/mL tAdn and 0.07 with 5 µg/mL tAdn. 
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Figure 3.28 Effect of 24 h pre-incubation with trimer adiponectin (tAdn) on 
oleic acid oxidation and acid soluble metabolites. Differentiated myotubes were 
pre-incubated 24 h with medium containing 0 (control), 0.1, 0.5, 1 and 5 µg/mL 
tAdn. Myotubes were then incubated for 4 h with [1-14C]oleic acid (1 µCi/mL, 50 
µM), 0.2 % Fetal Calf Serum (FCS), L-carnitine (1 mM) and glucose (5 mM). 
Means ± SEM are given as absolute quantities of 12 parallels (3 individual 
experiments with 4 parallels each). Asterisk (*) indicates significant oleic acid 
oxidation change compared to control (P ≤ 0.05, paired student t-test).  
 
A medium concentration of 1 µg/mL tAdn significantly decreased oleic acid oxidation by 48 
% (P≤0.05) compared to myotubes pre-incubated without tAdn (figure 3.28). Other tAdn 
concentrations (0.1, 0.5 and 5 µg/mL) seemed to decrease oleic acid oxidation, but these 
reductions were not statistically significant.  
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Figure 3.29 Effect of acute incubation with trimer adiponectin (tAdn) on Cell-
associated radiolabel and glucose oxidation.  Differentiated myotubes were 
incubated for 4 h with [6-14C] glucose (1 µCi/mL, 100 µM) and 0.2 % Fetal Calf 
Serum (FCS). Medium tAdn concentrations were 0 (control), 0.1, 0.5, 1 and 5 
µg/mL. Means ± SEM are given as absolute quantities of 12 parallels (3 individual 
experiments with 4 parallels each). Asterisk (*) indicates significant CAR change 
compared to control (P ≤ 0.05, paired student t-test). 
 
Trimer adiponectin concentrations of 0.5, 1 and 5 µg/mL, significantly reduced CAR values 
by 19, 29 and 36 % (p≤0.05) respectively (figure 3.29).  
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Figure 3.30 Effect of 24 h pre-incubation with trimer adiponectin (tAdn) on 
cell-associated radiolabel and glucose oxidation. Differentiated myotubes were 
pre-incubated 24 h with medium containing 0 (control), 0.1, 0.5, 1 and 5 µg/mL 
tAdn. Myotubes were then incubated for 4 h with [6-14C]glucose (1 µCi/mL, 100 
µM) and 0.2 % Fetal Calf Serum (FCS). During the 4 hour incubation the medium 
did not contain tAdn. Means ± SEM error bars are given as absolute quantities of 
12 parallels (3 individual experiments with 4 parallels each). 
 
No effects of tAdn were observed on CAR when pre-incubating myotubes for 24 h before 4 
h incubation with labeled glucose (figure 3.30).  
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Figure 3.31 Effect of acute incubation with trimer adiponectin (tAdn) on cell-
associated radiolabel and oleic acid oxidation. Differentiated myotubes were 
incubated for 4 h with [1-14C]oleic acid (1 µCi/mL, 50 µM), 0.2 % Fetal Calf Serum 
(FCS), L-carnitine (1 mM) and glucose (5 mM). Medium tAdn concentrations were 
0 (control), 0.1, 0.5, 1 and 5 µg/mL. Means ± SEM are given as absolute quantities 
of 12 parallels (3 individual experiments with 4 parallels each). Asterisk (*) 
indicates significant oleic acid and CAR change compared to control (P ≤ 0.05, 
paired student t-test).  
 
A concentration of 1 µg/mL tAdn significantly increased measured CAR values by 9 percent 
(p≤0.035) compared to the myotubes incubated without adiponectin (figure 3.31). For the 
other tAdn concentrations no significant CAR changes were found.   
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Figure 3.32 Effect of 24 h pre-incubation with trimer adiponectin (tAdn) on 
cell-associated radiolabel and oleic acid oxidation. Differentiated myotubes 
were pre-incubated 24 h with medium containing 0 (control), 0.1, 0.5, 1 and 5 
µg/mL tAdn. Myotubes were then incubated for 4 h with [1-14C]oleic acid (1 µCi/mL, 
50 µM), 0.2 % Fetal Calf Serum (FCS), L-carnitine (1 mM) and glucose (5 mM). 
During the 4 hour incubation the medium did not contain tAdn. Means ± SEM error 
bars are given as absolute quantities (n=12) (3 individual experiments with 4 
parallels each). 
 
As seen in figure 3.32, there seemed to be a tendency for increase in oleic acid oxidation 
with increasing adiponectin concentration. However, these apparent dose response changes 
were not statistically significant.  
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4. Discussion 
4.1 Effect of FAs on HepG2 cell AR1/2 mRNA expression 
In this study the amount of adiponectin receptors were significantly reduced by saturated 
FAs in most incubations for AR1, but not AR2. No coherence regarding concentration of FA 
and reduction of AR was found. A significant reduction in AR for the lowest concentration 
of FA was not observed for the higher FA concentration. Earlier experiments with HepG2 
cells incubated with palmitic acid (16:0) for 24 h had shown a possible reduction in 
adiponectin receptor mRNA (19;20). This is consistent with the findings of Sun et al that the 
amounts of AR2 were increased, but not the amounts of AR1. The insulin-sensitizing 
activities of PPARγ agonists are associated with their ability to decrease circulating levels of 
free FAs through inhibition of adipocyte lipolysis, as well as regulation of proteins 
(adiponectin receptor 1 and 2) that modulate insulin sensitivity and lipid metabolism (22). 
The reduction in expression of AR 1 and 2 mRNA was more evident for HepA compared to 
the other FAs (figure 3.4). All FAs used in these experiments were saturated with increasing 
carbon chain length. There seemed to be no correlation between increasing FA carbon chain 
length and decreasing AR mRNA expression. No published experiments with HepG2 cells 
and the FAs used were found, making comparison with other experiments difficult. 
The FA analogue tetradecylthioacetic acid (TTA) was found to inhibit secretion of 
triacylglycerol from rat hepatocytes, mainly by stimulating FA oxidation and then promote 
hypotriglyceridemia (23). The 3-thia FAs increase FA oxidation in liver through inhibition 
of malonyl-CoA synthesis, activation of carnitine palmitoyl transferase I (CPT I), and 
induction of carnitine palmitoyl transferase II (CPT-II) and enzymes of peroxisomal β-
oxidation. Activation of FA oxidation is the key to the hypolipidemic effects of 3-thia FAs. 
Also other lipid metabolizing enzymes are induced. The mechanism of enzyme induction 
seen with TTA is not completely understood, but the peroxisome proliferator activated 
receptor (PPARα) may be involved (24). From our experiments, no significant reduction in 
the expression of AR1 or AR2 mRNA were observed when liver cells were incubated for 24 
h with the FA analogues at three different concentrations (50, 100 or 200 µM).  This is 
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consistent with what has been published regarding TTAs metabolic effects on liver cells 
(23;24).  
Studies have shown that FAs may participate in the regulation of gene expression. The exact 
mechanisms (specific binding to various nuclear receptors or changes in the abundance of 
regulatory transcription factors) by which FAs exert their effects are not fully understood, 
but non-esterified FAs or their CoA derivatives seem to be the main signals involved in the 
transcriptional effect of long-chain FAs (25).  
Several of the experiments done with expression of adiponectin receptor regulation have 
been performed on mice and rats feed high fat diets rich in saturated FAs. The only 
modification of adiponectin receptor expression observed when feeding rats high fat diets 
rich in saturated FAs, was a decrease in liver AR2 mRNA concentrations (14). Adiponectin 
receptor expression in rats is poorly responsive to modification of nutritional conditions and 
this expression was not decreased in a genetic model of insulin resistance (14). Neumeier et 
al found that in fasted mice, the AR1 and AR2 mRNA were induced in the liver, and re-
feeding decreased the expression. This suggests that a reduced expression of adiponectin 
receptors may contribute to fatty liver disease in obesity and metabolic syndrome (26). 
However, these results do not indicate a regulation of adiponectin receptors by FAs, and no 
published studies have been performed with these FAs regarding effect on the expression of 
adiponectin receptors in humans. Staiger et al tested whether there is a correlation between 
AR1 mRNA expression and plasma free fatty concentrations. No association could be found 
by simple and multivariate linear regression analysis (27).  
The expression of adiponectin receptors is regulated by different pathways in different cell 
types, and regulation is likely to be associated with altered glucose and lipid metabolism in 
either T2D cells or after incubation with antidiabetic drugs (22). Functional involvement of 
the glucocorticoid receptor (GR) element in the regulation of adiponectin receptor 2 in liver 
cells has been shown. The increased expression of AR2 is expected to lead to an increased 
sensitivity of liver cells to adiponectin and thereby to enhancement of the antidiabetic 
activity of adiponectin (22). Sun et al found that the PPARγ agonist rosiglitazone was able to 
elevate both the mRNA and protein levels, as well as to stimulate promoter activity of 
adiponectin receptor 2, but not 1 in HepG2 cells (22).  
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Kadowaki et al found that the levels of AR1 and AR2 mRNA expression in the liver and 
skeletal muscle increased after fasting, and refeeding rapidly restored these to levels equal to 
the original fed state (8). The amounts of FAs in plasma were increased after fasting. This 
study was based on a 24 hour experiment, and if the changes in gene expression were 
induced rapidly, this would not be revealed. The effect of FAs on longer time intervals was 
not measured in this experiment. Similar problems were seen in our experiments. This was 
the same challenges with the experiments performed in our study.  
The distribution of different adiponectin receptors varies greatly, as have been described in 
other studies. In these experiments we have just looked at HepG2 cell mRNA expression, 
which can be different in other hepatic cell lines, primary cells and cells in situ. Further 
experiments are needed to investigate the tendency of saturated FAs to reduce the amounts 
of AR1 and 2 mRNA to draw any clear conclusions. 
4.2 T-cadherin, adiponectin receptor 3 
T-cadherin was most abundantly expressed in fetal brain, heart, uterus, lung and skeletal 
muscle (fig 3.8). The result of our analyzes was consistent with other findings, where 
Bromhead et al found that T-cad was expressed widely in the brain, the cardiovascular 
system and also in lung and heart (10). The distribution of T-cad was distinct from the 
distribution of AR1 and AR2. AR1 mRNA was relatively highly expressed in skeletal 
muscle, but even higher in other tissues like testis, placenta and fetal liver. AR2 mRNA was 
highly expressed in liver, both fetal and adult (19;20). AR1 and AR2 are GPI anchored 
receptors compared to T-cad, which is an extracellular receptor. AR3 was first identified as a 
cadherin receptor, and later as an adiponectin receptor. 
The amount of T-cad mRNA was measured quantitatively with both real-time PCR and by 
semi-quantitative methods like western blotting in the study by Bromhead et al (10).  The 
amount of T-cad mRNA was measured quantitatively only by real-time PCR in our 
experiment.  
The tissue distribution of T-cad was found after analyzing only one single tissue panel from 
ACCT. To get a more certain picture of the T-cad distribution in the body we need to 
analyze other tissue panels and see if they display the same results since there may be inter 
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individual variations in distribution of T-cad. Adiponectin receptors have selective affinity 
to the amount and different types of adiponectin in plasma. T-cad is a receptor for hexameric 
and high-molecular-weight (HMW) forms of adiponectin, but not for the trimeric and 
globular adiponectin (10). Based on the assumption that there is an inverse correlation 
between plasma levels of adiponectin and T-cad, this may explain the low amounts of T-
cadherin receptors since it binds HMW adiponectin and almost all adiponectin appears to 
exist as full-length adiponectin in plasma (8). If this assumption is correct, low amounts of 
receptors are needed to exert effects of adiponectin. 
The objective for these experiments was to analyze the effect of FAs on T-cad mRNA 
expression in HepG2 cells, as had been done for AR1 and AR2. Due to low amounts of T-
cad receptor in these cells, this was not possible. The low amounts of T-cad in liver were 
confirmed when we looked at the results from the tissue panel analysis, (fig 3.8). Lee (1996) 
found that T-cad is hardly detectable in the liver (28) which is consistent with our finding. 
Further experiments with HepG2 cDNA and the expression of T-cadherin receptor were not 
performed. 
4.3 Human myotubes  
Globular adiponectin seems to increase the amount of oleic acid oxidation more than full-
length adiponectin and trimer adiponectin in human myotubes in our experiments. Civitarese 
et al. found that adiponectin incubation increases mitochondrial bioenergetics in primary 
human myotubes (12). Two days incubation with 0.25 and 0.5 µg/mL of gAdn increased 
mtDNA content (12). In our experiments the preincubation with gAdn did not significantly 
increased FA oxidation in human myotubes compared to the control cells incubated with no 
gAdn (fig 3.16 to 3.21). Yamauchi et al. have shown that 2-week administration of full-
length or globular head domain of adiponectin to mouse models of obesity and lipoatrophy, 
reversed insulin resistance associated with both lipoatrophy and obesity. Also, chronic 
infusion of a very low dose of gAdn in mice consuming a high-fat and high-sucrose diet 
prevented development of obesity without affecting food intake (29). But these results can 
not be generalized directly to human myotubes.  
Yoon et al. showed that adiponectin increases FA oxidation via activation of AMPK and 
phosphorylation of ACC. However, the phosphorylation of ACC induced by adiponectin is 
 74 
short-lived (30). Therefore, this pathway may not fully explain the long-term effects of 
adiponectin on weight loss and FA oxidation. On the other hand, activation of PPARα would 
be a promising pathway by which adiponectin can trigger long-term stimulation of FA 
oxidation, even when initial signaling is not present. This would probably increase the 
amounts of relatively long-lived enzymes involved in FA metabolism (30). PPARα is a 
ligand-activated nuclear hormone receptor that is highly expressed in tissues that obtain 
most of their energy from FA oxidation, including liver, heart, kidney and skeletal muscle. 
PPARα controls the expression of a number of genes involved in peroxisomal and 
mitochondrial β-oxidation, such ACO (acyl-CoA oxidase), CPT1 and FABP3 (fatty acid 
binding protein 3) (30). Expression of PPARα in the myotubes used in our experiments was 
not analyzed. 
There are few published experiments testing the effect of different types of adiponectin on 
myotubes and fatty acid (FA) oxidation. We expected to observe an increase in β-oxidation 
in the myotubes, at least for the experiments with globular adiponectin since adiponectin 
receptor-1 is abundantly expressed in skeletal muscle and is a high-affinity receptor for 
globular adiponectin (31). Adiponectin receptor-2 expression is restricted to muscle and 
liver and has intermediate affinity for globular and full-length adiponectin. Previous studies 
have shown differences in biological activity between globular and full-length adiponectin 
(32). A proteolytic cleavage product of adiponectin that includes its globular head group 
(gAdn), induces FFA oxidation and glucose uptake in muscle, whereas full-length 
adiponectin has been shown to inhibit hepatic glucose production (32).  
It is well established that AMP-activated protein kinase (AMPK) in skeletal muscle cells 
increases FA oxidation by inhibiting acetyl-CoA carboxylase (ACC) through 
phosphorylation. A decrease in ACC activity reduces intracellular malonyl-CoA. Since 
malonyl-CoA is an allosteric inhibitor of carnitine palmitoyl transferase 1 (CPT1), a 
repressed production will increase CPT1 activity. This ultimately increases influx of long-
chain FAs into the mitochondria where they are oxidized (30). This could not be observed on 
our experiments.  
The CO2 trapping method used in our experiments with myotubes is described in a recent 
paper by Wensaas et al. (33). The measurement of acid soluble metabolites (ASM), cell-
associated radioactivity (CAR) and CO2 are well established methods. It is generally 
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accepted to use ASM as a measure of FA oxidation, alone or in parallel with CO2 
measurements (34). Direct measurements of CO2 production were done in parallel with 
ASM production, as a measure of FA oxidation. CO2 measures the flux into Krebs cycle, 
whereas the sum of CO2 and ASM measures total fatty acid oxidation. 
No effect on glucose oxidation or uptake was seen for the myotubes preincubated with tAdn 
and later incubated with labeled glucose medium. A significant increase was observed in 
CO2 measurements for myotubes incubated with 1 µg/mL tAdn and glucose labeled medium 
(fig 3.23) and for CAR measurements from the same experiment at 0.5, 1 and 5 µg/mL (fig 
3.29). The reason for the different results could be that the effect of tAdn on glucose 
metabolism could be short lasting. Since only two pre-incubation times were investigated, 
there was no information regarding when the onset of the prospective maximum rate of 
glucose metabolism happens and when a prospective decrease begins. More experiments are 
needed to reveal effects of tAdn concentrations between 1 and 5µg/mL to assess dose-
response effects properly. No studies were found having performed comparable experiments 
with tAdn.  
Bruce et al found that administration of the globular head of adiponectin (1 h incubation 
together with [1-14C]palmitate) reduces plasma glucose levels and ameliorates insulin 
resistance in mice (31). Recent studies have also shown that incubation of isolated rodent 
skeletal muscle with globular adiponectin stimulates glucose uptake (31). Globular 
adiponectin increases glucose uptake in the absence of insulin in skeletal muscle from both 
lean and obese individuals (31). It has been reported that adiponectin increases glucose 
uptake in skeletal muscle, apparently via activation of AMPK. It remains to be determined 
whether adiponectin increases GLUT4 translocation in skeletal muscle or not (35). Ceddia et 
al investigated the effect of globular adiponectin (gAdn) on GLUT4 translocation, glucose 
uptake, glycogen synthesis, glucose oxidation, lactate production and FA oxidation in 
muscle cells in culture (35). They found that gAdn increases glucose uptake in skeletal 
muscle cells via GLUT4 translocation and subsequently reduces the rate of glycogen 
synthesis and shifts glucose metabolism toward lactate production. These effects are 
consistent with the increased phosphorylation of AMPK and ACC and oxidation of FAs 
induced by globular adiponectin (35). More experiments are needed to assess long-term 
effects on dose-response of tAdn on glucose oxidation.  
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Only a few experiments with trimer adiponectin have been published, making it difficult to 
compare our experiment with similar findings. One experiment used skeletal muscle in rats. 
Tsao et al. showed that only trimeric adiponectin, not hexameric or HMW adiponectin 
isoforms activated AMPK in skeletal muscle from rats (36). 
Species difference between human myotubes and rodents and inter-individual variation in 
tissues examined, may explain the difference between our results and published literature 
where adiponectin significantly increased FA oxidation. The method used in these 
experiments is relatively new. The use of different methods may contribute to non-existing 
variation. Myotubes or primary muscle cells from three different donors were used: lean, 
obese and obese type 2 diabetic. The amounts of adiponectin receptors in the myotubes from 
these donors were not measured, although this would be an interesting variable to investigate 
further. The results from our experiments were calculated by using paired t-test. Too few 
experiments were performed to assess any effect of tAdn. 
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5. Conclusion and future perspectives 
Experiments with HepG2 cells  
This study showed that incubating HepG2 cells with saturated fatty acids (FAs) had a 
tendency to reduce the amounts of adiponectin receptor 1 (AR1). The results showed 
inconsistency with respect to increasing concentrations of FA and a further reduction in AR 
expression levels. For AR2 a significant reduction was seen only when preincubating HepG2 
cells with 50 µM stearic acid. The FA analogues (TTA, αTTA TTTA) did not alter the 
expression of AR in HepG2 cells.  Due to inconsistent results with respect to concentration 
of FA and the reduction of AR1 expression levels, further experiments are needed to assess 
whether FA reduces the expression of adiponectin receptors.  
FA can influence the effect of adiponectin in other ways than just downregulation of the 
adiponectin receptors. The regulation could be downstream of the receptor. The amount of 
AMPK or other intracellular signal substances should be investigated to see if FA incubation 
results in any change. Expression of the human AR1 and AR2 genes may be different in 
other hepatic cell lines, primary cells and cells in situ. It has also been emphasized that 
transcription studies in cell cultures do not necessarily reflect processes in vivo. 
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Expression of T-cadherin 
T-cad was mostly expressed in fetal brain, heart, uterus, lunge and skeletal muscle and 
hardly detectable in liver. The amounts of T-cad in malign lymphoid cell lines were 100 to 
1000 fold lower than the amounts in myotubes. The distribution of T-cad was distinct from 
the distribution of AR1 and AR2. More studies are needed to survey the effect downstream 
of T-cad. 
T-cad as an adiponectin receptor (AR3) was discovered in 2004, and is thus relatively new. 
This receptor is different from AR1 and AR2 and the tissue distribution also differs. Since 
the amounts of receptor are relatively low in liver it may be challenging to study down-
regulation by different substances similar to the experiments done with AR1 and AR2.  
Human myotubes and adiponectin 
Incubation of human myotubes with adiponectin showed inconsistency with respect to the 
effect on FA oxidation. Full-length adiponectin, globular adiponectin and trimeric 
adiponectin were used.  Globular adiponectin seemed to increase the amount of oleic acid 
oxidation more than full-length adiponectin and trimer adiponectin. Trimer adiponectin 
seemed to increase the amount of glucose oxidation. More experiments are needed to assess 
the effect of adiponectin on fatty acid and glucose oxidation.  
Adiponectin is a potent bioactive substance, with the ability to increase FA oxidation in 
human myotubes. This is seen for globular adiponectin in several studies. The effect of 
trimer adiponectin has not been investigated as thoroughly. The amounts of adiponectin 
receptors should be investigated in the myotubes. Human myotubes is suited for these 
experiments since the amount of adiponectin receptors are found to be relatively high. The 
CO2 trapping method is suited for these types of metabolic experiments, and thus should be 
considered as an appropriate system for future experiments.  
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Appendix  
Culture medium for HepG2 cells 
500 ml MEM medium (Sigma, #M2279) 
50 ml heat inactivated fetal calf serum (FCS) (Sigma, #F7524) 
5 ml penicillin –streptomycin (sigma, #P4333, 10000 U/mL penicillin, 10 mg/mL 
streptomycin) 
5 ml L-glutamine (Sigma, #G7513) 
5 ml non-essential amino acid solution (Sigma, #M7145, 100x) 
5 ml sodium-pyruvate (Sigma, #S8636, 11 mg/mL) 
Making FAs stock, for experiments with HepG2 cells 
 
Bovine serum albumin solution (BSA), without fatty acids. 
Mw 67.000, 2.5 mM concentration 
Taking the average value for the different FAs, approximately 67 µl 
161 mg BSA solved in 933 µl DMEM, 8 g BSA in 46.65 ml DMEM. 
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Making of fatty acid solutions 
Final concentration 6mM in bovine serum albumin (BSA) 
0.025 g of each FA was solved them in DEPC water. As a sodium salt the FAs were easily 
solved, otherwise they were solved in 0.1M NaOH.  
The suspensions were heated in a water bath holding 96˚C. BSA was heated to 50˚C and 5 
ml BSA added to each of the FAs and mixed thoroughly. The final concentration of the 
different FAs was 6 mM. When the liquid were clear they were sterile filtered and batched 
out in 2 ml plastic tubes. Store at -20˚C. 
Before the FAs were added to the HepG2 cells they were diluted with DMEM medium to 
concentrations of 200, 100 and 50 µM.  
The wells were added FAs and let to stand 24 h before they were harvested. 
 
Bovine Serum Albumin 6 %, BSA  
Measure up 1.2 g bovine serum albumin with FAs in to a 50 ml plastic tube. Add 18 ml 
milliQ water. Turn the tube to dissolve the powder. If much foam, spin down  
Medium for human skeletal muscle cells 
M0- medium: 
500 ml DMEM low glucose (Sigma, #D6046) 
10 ml FCS (Fetal Calf Serum, not heat inactivated, Sigma #F7524) -2 % 
5 ml Penicillin/Streptomycin (Gibco BRL, #15140-114, 100ml) 
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M1- seeding: 
500 ml DMEM low glucose (Sigma, #D6046) 
50 ml FCS (Fetal Calf Serum, not heat inactivated, Sigma #F7524) -10 % 
5 ml Penicillin/Streptomycin (Gibco BRL, #15140-114, 100ml) 
(Take out 25 ml from M0-medium and add 2 ml FCS) 
M2- Proliferation: 
500 ml DMEM low glucose (Sigma, #D6046) 
10 ml FCS (Fetal Calf Serum, not heat inactivated, Sigma #F7524) -2 % 
10 ml Ultroser-G, UG (Bio Serpa, #15950-017) 
5 ml Penicillin/Streptomycin (Gibco BRL, #15140-114, 100ml) 
(Take out 200 ml from M0-medium and add 4 ml UG) 
M3- Differentiation: 
500 ml DMEM low glucose (Sigma, #D6046) 
10 ml FCS (Fetal Calf Serum, not heat inactivated, Sigma #F7524) -2 % 
5 ml Penicillin/Streptomycin (Gibco BRL, #15140-114, 100ml) 
25pmol Insulin (21 µl of 1000 x diluted Insulin Actrapid, Novo Nordisk 0.06 mM) 
(Take out 24 ml from M0-medium and add 1 µl 25pmol/µl Insulin)  
Ultroser-G (Bio Serpa, #15950-017) should be re-constituted by adding 20 ml MQw to the 
container. Wait for 15 min, sterile filtrate and transfer 10 ml to the M2- medium. The rest is 
frozen (-20ºC) for further use. 
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Making radioactive oleic acid, 0.1µCurie/µl 
Take out 50 µl radioactive oleic acid in ethanol. Use N2 gas to evaporate the ethanol to a 
volume of 5-10 µl. Add 20 µl 0.01 M NaOH, vortex 1-2 min. Add 16 µl BSA (2.4 mM in 
PBS) and vortex 1 minute. Heat for 15-30 min, vortex and spin down. Transfer to plastic 
tube witch contain 5 ml sterile filtrated PBS. Add 5 ul l-carnitine (1M) and 25 ul glucose (1 
M).  
Making Luria-Bertani (LB) medium and LB agar 
Mix 10 g peptone, 5 g yeast extract and 10 g NaCl in a 1 liter glass bottle. Add 
approximately 950 ml MilliQ water. Adjust the pH to 7.0 at 23˚C, with NaOH 1 M. Adjust 
the volume to 1 liter. Autoclaver the liquid. Cool down to 55˚C and add antibiotics. Store at 
room temperature or 4˚C. 
Make 1 liter LB medium, adjust the pH to 7.0 and add 15 g agar. Autoclave. Cool down to 
55 ˚C and add Kanamycin to the concentration (50 µg/µl). Pour 20 ml of the liquid over 10 
cm Petri dishes. Let the liquid stiffen, turn the dishes upside down an store at 4˚C.  
Calculations 
 
AR1: The vector is 1127 bp + 2580 bp = 3707 bp 
         The molecule weight per bp = 660 g/mol 
         3707 bp x 660 g/mol =2446620 Mw 
         Standard for AR1 10-13/2µl x 6.022x 1023 =24614 copies/2 µl 
                     Mw AR1 
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AR2: The vector is 1160 bp + 2580 bp = 3740 bp 
         The molecule weight per bp = 660 g/mol 
         3740 bp X 660 g/mol =2468400 Mw 
         Standard for AR2 10-13/2µl x 6.022x 1023 =24396 copies/2 µl 
                     Mw AR2 
 
T-Cad/AR3: The vector is 2141 bp + 2580 bp = 4721 bp 
         The molecule weight per bp = 660 g/mol 
         4721 bp X 660 g/mol =3115860 Mw 
         Standard for AR3 10-14/2µl x 6.022x 1023 =1933 copies/2 µl 
                     Mw AR3 
 
RPL27: The vector is 410 bp + 2580 bp = 2990 bp 
         The molecule weight per bp = 660 g/mol 
         2990 bp X 660 g/mol =1973400 Mw 
         Standard for RPL27 10-11/2µl x 6.022x 1023 =3051586 copies/2 µl 
                     Mw RPL27 
